Genetic polymorphisms, platelet activation and plasma homocysteine concentrations in atherothrombotic stroke by Meiklejohn, David J
 
 
 
 
 
 
 
https://theses.gla.ac.uk/ 
 
 
 
 
Theses Digitisation: 
https://www.gla.ac.uk/myglasgow/research/enlighten/theses/digitisation/ 
This is a digitised version of the original print thesis. 
 
 
 
 
 
 
 
 
Copyright and moral rights for this work are retained by the author 
 
A copy can be downloaded for personal non-commercial research or study, 
without prior permission or charge 
 
This work cannot be reproduced or quoted extensively from without first 
obtaining permission in writing from the author 
 
The content must not be changed in any way or sold commercially in any 
format or medium without the formal permission of the author 
 
When referring to this work, full bibliographic details including the author, 
title, awarding institution and date of the thesis must be given 
 
 
 
 
 
 
 
 
 
 
 
 
 
Enlighten: Theses 
https://theses.gla.ac.uk/ 
research-enlighten@glasgow.ac.uk 
Genetic polymorphisms, platelet 
activation and plasma homocysteine
concentrations in atherothrombotic
stroke.
David J Meiklejohn BSc MBChB
Thesis submitted for the degree of MD to the University of 
Glasgow, June 2000.
ProQuest Number: 10656445
All rights reserved
INFORMATION TO ALL USERS 
The quality of this reproduction is dependent upon the quality of the copy submitted.
In the unlikely event that the author did not send a com p le te  manuscript 
and there are missing pages, these will be noted. Also, if material had to be removed,
a note will indicate the deletion.
uest
ProQuest 10656445
Published by ProQuest LLO (2017). Copyright of the Dissertation is held by the Author.
All rights reserved.
This work is protected against unauthorized copying under Title 17, United States C ode
Microform Edition © ProQuest LLO.
ProQuest LLO.
789 East Eisenhower Parkway 
P.Q. Box 1346 
Ann Arbor, Ml 48106- 1346
fGLASGOW
UNmSRSÂTY
U4-4 4
L P P ^  X
Coronal section, cerebral infarction
Acknowledgements
There are many people I wish to thank for their help in performing the work for 
and writing this thesis. I am grateful to Isobel Ford in the Haematology research 
laboratory at the University of Aberdeen, and David Stevenson, Irene Moore and 
Nicholas Robinson at the Immunology Lab at the Blood Transfusion Service for 
their advice and help with FACS analysis and PGR techniques. I thank the staff 
of the Medical Wards at Aberdeen Royal Infirmary for their cooperation with 
patient recruitment. I am grateful to Mark Vickers for continuing recmitment to 
ensure as few patients as possible were missed if I was on leave, and for his very 
helpful suggestions regarding the manuscript.
Special thanks are due to Professor Mike Greaves, who enabled me to carry out 
this work, and who has been a source o f great encouragement and inspiration 
throughout.
This work was performed thanks to research grants from Chest, Heart and Stroke 
(Scotland), and the Aberdeen Royal Hospitals Endowment Fund.
Dedication
This thesis is dedicated to Linda and Laura.
Contents
Section Page
Declaration i
Summary ii
Chapter one. Introduction. 1-27
1.1 Definitions and epidemiology 2
1.2 Pathophysiology of atherothrombotic stroke 3
1.3 Platelet activation in acute arterial thrombosis 4
1.4 Platelet membrane glycoproteins 8
1.5 Risk factors for atherothrombotic stroke 10
1.6 Candidate genetic polymorphisms 11
1.7 Outline of studies undertaken_________________________________________________ 17
Chapter two. Patient and volunteer recruitment, sample handling 28-40
and characteristics.
2.1 Platelet donor study 29
2.2 Stroke study 30
2.3 Results 33
Chapter three. An investigation of the effect of HP A la/lb  
genotype on platelet fibrinogen binding in healthy subjects.
41-55
3.1 Background 42
3.2 Aims 43
3.3 Methods 44
3.4 Results 48
3.5 Discussion 49
Chapter four. In vivo platelet activation in atherothrombotic 
stroke: relationship to polymorphisms of platelet GPHIa and
GPIb.
56-88
4.1 Background 57
4.2 Aims 58
4.3 Methods 59
4.4 Results 71
4.5 Discussion 75
Chapter five. Plasma Homocysteine concentrations in the acute 89-112 
and convalescent phases of atherothrombotic stroke.
5.1 Background 90
5.2 Aims 93
5.3 Methods 94
5.4 Results 101
5.5 Discussion 103
Chapter six. The contribution of Factor VII gene polymorphisms 113-126 
to longevity
6.1 Background 114
6.2 Methods 115
6.3 Results 119
6.4 Discussion________________________________________________________________ 120
Chapter seven. Conclusions . 127-144
7.1 Platelet polymorphism studies 129
7.2 Functional studies of platelet polymorphisms 135
7.3 Homocysteine as a causative risk factor 136
7.4 Conclusions_______________________________________________________________ 138
References 145-180
Appendices 181-197
I Reagents 182
II Patient and control information sheets 190
III Publications arising from this thesis. 196
Declaration
I declare that I am the author of this thesis, and that all references cited have been 
consulted by myself. I personally performed the following: recruitment and 
sampling of all subjects described in this thesis; flow cytometric analysis of the 
donors described in chapter two, and o f the patients and controls in chapter three; 
HP A la /lb  genotyping o f patients and controls; R353Q genotyping of 60 subjects 
described in chapter four; plasma homocysteine assays by HPLC described in 
chapter five; and for all data analyses. I also had the following help: Miss Irene 
Moore o f the North East of Scotland Blood Transfusion Service performed the 
HP A la /lb  genotyping of the donors described in chapter two and the HP A 2a/2b 
genotyping of patients and controls described in chapter three; Dr Rona Morrison 
was of invaluable help in preparing samples for DNA extraction, plasma 
separation and flow cytometric analysis of a substantial number of patients and 
controls; Mr Neil Youngson and Ms Zoe Riches performed the FVII gene 
polymorphism analyses in chapter four. I am very grateful to each for their 
assistance. This work was carried out between June 1997 and May 1999 while I 
was a Research Registrar in Haematology at Aberdeen Royal Infirmary. No part 
o f this work has previously been accepted for a higher degree.
David J Meiklejohn. June 2000
11
Summary
Atherothrombotic stroke arises following rupture of an atheromatous plaque, and 
occlusion occurs directly due to thrombosis in small arteries, or indirectly by 
embolisation if a large vessel plaque ruptures. Three risk factors that are claimed 
to influence these process were investigated.
• The influence of platelet activation and genetic polymorphisms of platelet 
membrane glycoproteins on the risk of thrombotic stroke was assessed. 
Following plaque rupture, platelets have a pivotal role in arterial thrombus 
formation, and platelet membrane glycoproteins (GP) Ilia  (the fibrinogen 
receptor) and Ib (which binds von Willebrand factor) are crucial in this 
process. The lb  allele of the HP A la /lb  GPIIIa polymorphism and the 2b 
allele of the HP A 2a/2b GPIb polymorphism are claimed to be risk factors for 
stroke and myocardial infarction (MI), but reports are conflicting and 
consistent functional evidence of enhanced thrombogenicity is lacking.
• Increased factor VII activity (VIIc) has been claimed to be a risk factor for MI 
and stroke, but the data are conflicting. VIIc is dependent on both 
environmental and genetic influences, and recently two polymorphisms of the 
factor VII gene associated with lower VIIc have been claimed to be protective 
against MI.
» A raised plasma homocysteine concentration has been proposed as a cause for 
atherosclerosis. However the role of homocysteine in stroke aetiology remains
Ill
controversial, since prospective studies have reported a weaker association 
than those conducted retrospectively. Furthermore there are few reports of 
plasma homocysteine concentrations both before and after the event.
The following studies were conducted to address these issues:
An investigation o f  the effect o f  HP A la /lb  genotype on platelet fibrinogen 
binding by whole blood flow  cytometry in healthy subjects.
The effect of the lb  allele on platelet fibrinogen binding was investigated in 
healthy subjects by whole blood flow cytometry. 35 platelet or plasma donors (34 
HP A la /lb  and one HP A lb /lb ) possessing the lb  allele were compared with 35 
donors homozygous for the la  allele. There was no allele dependent difference in 
the percentage of platelets binding fibrinogen at baseline (p=0,14, Mann Whitney 
U test) or following stimulation with ADP (p=0.72, Student’s /-test). An 
paradoxical increase in the density of fibrinogen binding sites was observed in la  
platelets after ADP stimulation (p=0.05, Mann Whitney U test), lb  platelets 
tended to exhibit greater activation as assessed by the percentage o f platelets 
expressing P-Selectin, but this did not reach statistical significance (p=0.08, 
Mann-Whitney U test). These data do not identify a functional mechanism by 
which the lb  allele might mediate an increased risk o f arterial thrombosis.
In vivo platelet activation in atherothrombotic stroke: relationship to
polymorphisms o f  human platelet GPIIIa and GPIb.
IV
The expression of platelet activation markers in 150 consecutive patients (98 
male/52 female; mean age 58.3) with acute atherothrombotic stroke was measured 
usually within 24 hours of the onset of symptoms. Evidence of persisting platelet 
activation was sought in 77 patients who reattended in the convalescent period 
(mean 100 days). The lb  and 2b allele frequencies were determined, and the 
influence o f genotype on platelet activation was assessed. Results were compared 
with 150 healthy age and sex matched controls recruited from a local general 
practice. Neither the lb  allele (allele frequency 0.11 vs 0.13, OR{CI} 0.8{0.5- 
1.3} nor the 2b allele (0.09 vs 0.07, OR{CI} 1.4{0.8-2.4} was significantly 
overrepresented in patients. Increased numbers of activated platelets were found 
following stroke (geometric mean acute P-Selectin expression 0.64% vs control 
0.35%, p<0.001, Student’s /-test; acute mean fibrinogen binding 1.6% vs control
0.9%, p<0.001. Student’s /-test). This persisted in the convalescent phase (P- 
Selectin 0.62%, fibrinogen binding 1.4%, p<0.001 and p=0.005 vs controls 
respectively). Expression of P-Selectin and fibrinogen was influenced by neither 
HP A la /lb  genotype (p>0.95 for each marker, Scheffe’s test), nor 2a/2b genotype 
( p>0.95 for each). Thus in vivo platelet activation and the relationship with 
platelet genotype was studied in acute thrombosis, and although persisting platelet 
activation was observed in atherothrombotic stroke, it remained independent of 
HP A la /lb  and 2a/2b genotype. These data suggest an underlying prothrombotic 
tendency, but do not support the polymorphisms studied as risk factors for 
thrombotic stroke in this population.
The influence o f  factor VII gene polymorphisms on longevity in the 
nonagenarians.
The hypothesis tested was that these polymorphisms are overrepresented in a 
group of nonagenerians from a region with high cardiovascular mortality, since 
reaching extreme old age should be favoured by avoiding stroke and MI. The 
frequencies of the Q allele of the R353Q polymorphism and H7 allele o f the IVS7 
polymorphism were determined in 113 subjects (86 female/ 27 male) over 90 
years of age (median 96; range 90-103) and 100 (80 female/ 20 male) younger 
controls (median 32 years; range 19-44). 15.6% enrichment of the Q (0.111 vs
0.096, p=0.61) and 9.7% enrichment of the H7 (0.395 vs 0.360, p=0.45) alleles in 
long-lived individuals was found. Although the frequencies o f the ‘protective’ 
RQ and H7H7 genotypes were over-represented in the study population, these 
differences were not statistically significant (p=0.36 and 0.3 respectively). These 
data help to quantify any possible effect of FVII polymorphisms on longevity and, 
if  the allele frequencies observed reflect the true magnitude of any effect, it is 
calculated that between 750 (for the H7 allele) and 1600 ( for the Q allele) 
subjects are required to attain statistical significance.
Plasma Homocysteine concentrations in the acute and convalescent phases o f  
atherothrombotic stroke.
Fasting total plasma homocysteine (tHcy) concentrations were measured 
immediately after acute atherothrombotic stroke by HPLC with fluorescence 
detection. 106 patients (59 men/ 47 women, mean age 57.2 {25-70}and 56.5 {26- 
69} years respectively) were recruited within 24 (up to 96) hours of onset, and 82 
patients were resampled in the convalescent phase. There was no significant 
difference in acute median tHcy between patients and matched controls (Men; 
9.2pmol/l{range 4.4-22.8} vs 8.7pmol/l{(4.9-20}, p=0.09, Mann Whitney U test;
VI
Women 8.Ijiimol/l{(4.8-32.3} vs 7.6|xmol/l {(3.3-14.4}, p=0.58). Median plasma 
concentrations increased significantly in the convalescent period (from 
8.5fxmol/l{4.8-19.2}to 10.1pmol/l{4.3-31.5}, p<0.001, Wilcoxon ranked signs 
test). Median convalescent Hey concentrations were greater in both men and 
women than in controls (p=0.03 and 0.05 respectively, Mann Whitney U test). 
This did not appear to be explained by a reduction in red cell folate or serum B12 
concentration, despite these factors being significant covariates on multiple 
regression analysis. Although mean convalescent creatinine concentrations 
increased by 4pmol/l, it is calculated (given a Beta weight o f 0.42) that this 
predicts a mean increase of only 0.3pmol/l, compared to the observed rise of 
1.6pmol/l, and is insufficient to fully explain the rise in convalescent tHcy. These 
data do not support the hypothesis that raised plasma homocysteine concentrations 
predate atherothiombotic stroke. Instead they offer explanation for the 
discrepancy between prospective and retrospective studies, and suggest that tHcy 
levels may be caused by the disease process itself.
Chapter One
Introduction
1.1 Definitions and epidemiology
Stroke or cerebrovascular accident (CVA) is defined as a sudden loss of global or 
focal cerebral function due to sudden interruption of the blood supply to the brain, 
and is the third most common cause of mortality in the developed world after 
ischaemic heart disease and cancer (Warlow, 1996). The annual incidence of first 
stroke in the United Kingdom is two per thousand, but this increases with age, 
50% of all events occurring in patients over the age of 75 (Warlow, 1996). In 
1997 cerebrovascular disease accounted for 11.7% of all deaths in the Scottish 
population, and varied with increasing age from 5.8% of deaths in those under 65 
to 13.4% in those aged 65 and older (Scottish Health Statistics, 2000).
Stroke can be classified pathologically (figure 1.1). Haemorrhage may arise in the 
subdural or subarachnoid spaces, or may be intracerebral. Infarction results from 
thrombotic occlusion of a brain supplying artery, and symptoms reflect ischaemia 
in the territory it supplies. Thrombus may arise from local atheromatous disease, 
or may form proximally and dislodge, occluding a vessel distally. Half of such 
emboli arise from the heart, e.g. due to atrial fibrillation, valvular heart disease or 
mural thrombus, and the other half from proximal arterial disease, especially of 
the carotid vessels. When considering risk factors for stroke it is important to 
recognise that any risk factor may influence only one o f these very different 
processes. This thesis therefore limits investigation to stroke arising from the 
single pathophysiological process of atherothrombosis.
1.2 Pathophysiology of atherothrombotic stroke
The dominant arterial lesion responsible for atherothrombotic stroke and 
myocardial infarction is the atherosclerotic plaque. The ‘response to injury 
hypothesis’ has been proposed to explain the development of atheroma (Basha & 
Sowers, 1996). An inflammatory endothelial response is thought to be the 
initiating process in atheroma formation, with ongoing inflammation contributing 
to lesion development (Ross, 1999). This is supported by the observation that C- 
reactive protein (CRP) concentration is an independent risk factor for myocardial 
infarction (MI) and stroke (Ridker et al, 1997a). The earliest lesion is the fatty 
streak, which is present from childhood. Monocytes, T lymphocytes and smooth 
muscle cells accumulate in the arterial intima. These secrete chemokines which 
stimulate smooth muscle proliferation and collagen deposition, contributing to 
arterial luminal narrowing (Basha & Sowers, 1996). Monocytes mature to 
macrophages which accumulate intracellular lipid and express tissue factor (TF). 
Ongoing inflammation and endothelial damage leads to accumulation o f these 
foam cells, and plaques are formed when extracellular lipid accumulates. The 
lipid core is surrounded by a fibrous cap, of collagen, elastin and proteoglycans.
There are two distinct types of plaque (Taubman et al, 1997). “Stable” plaques 
are predominantly fibrotic and heavily calcified. They progressively naiTow and 
are associated with chronic stable arterial disease. “Unstable” plaques are lipid 
rich and prone to fissuring and rupture, leading to exposure o f TF and thrombus 
propagation. The thrombus may either become organised and incorporated into 
the developing atheroma, or at a critical point cause abrupt vessel occlusion. This 
precipitates an acute event such as stroke, MI or unstable angina (Burke et al,
1997). Coagulation and platelet activation following plaque rupture are therefore 
crucial events in the pathogenesis of atherothrombotic stroke.
1.3 Platelet activation in acute arterial thrombosis.
The processes of coagulation and platelet activation are inextricably linked, since 
coagulation activation stimulates recruitment and activation o f platelets to the 
thrombus and vice versa. A natural anticoagulant system predominates in the 
resting physiological state, in order to ensure that blood circulates in the fluid 
phase. In arterial thrombosis homeostatic balance is altered in favour of 
thrombosis when a plaque ruptures, exposing the plasma and platelets to TF and 
subendothelial proteins.
Coagulation activation
Coagulation is mediated by a cascade of proteolytic reactions which begins when 
exposed plaque TF interacts with activated plasma factor VII (Vila) to activate 
factors IX and X. This results ultimately in the generation o f thrombin, which is 
required to cleave fibrinogen and produce a fibrin clot. Many o f these reactions 
require Ca^ + ions and phospholipid as cofactors.
Platelet recruitment and activation
Platelets provide this phospholipid template for fibrin generation, as well as 
forming a platelet plug. The action of platelets in thrombus formation can be 
summarised thus (del Zoppo, 1998):
• Platelet adhesion. Exposure of subendothelial collagen leads to platelet 
adhesion. This is mediated by surface membrane glycoprotein (GP) receptors.
In the conditions of high shear stress seen in narrowed arteries this 
predominantly occurs via binding o f collagen to high molecular weight 
multimers of von Willebrand Factor, which in turn bind to the GPIb portion of 
the GPIb-GPIX complex (Nurden, 1995). Platelets may also bind directly with 
collagen through the GPIa ligand.
• Platelet spreading. Ca?* dependent intracellular signal pathways resulting in 
actin polymerisation and pseudopodia formation are activated following 
platelet adhesion. These result in spreading and elongation, and the movement 
of the dense body and alpha-granule organelles to the centre o f the platelet.
• Platelet activation. Simultaneously activation occurs via a number o f specific 
agonist-receptor interactions. GPIb and GPIa ligand binding initiates 
intracellular activation signalling upon platelet adhesion. There are specific 
receptors and signalling pathways for agonists involved in platelet activation. 
The major agonists to activate platelets are collagen and thrombin, but positive 
feedback occurs via the actions of adenosine diphosphate (ADP), adrenaline, 
serotonin (5 HT) and arachidonic acid which are produced by platelet activation 
and granule release. The thrombin receptor is distinguished by the fact that 
thrombin generated from coagulation activation and from platelet 
degranulation cleaves it to mediate activation (Brass et al, 1994). Initiation of 
these pathways results in platelet aggregation, and in degranulation of dense 
bodies and alpha-granules. These contain a variety of compounds that promote 
platelet and coagulation activation and recruit circulating platelets to the 
developing thrombus. These include fibrinogen, collagen, vWF, platelet factor
4 (PF4), betathromboglobulin (b-TG) and P-Selectin from alpha-granules, and 
agonists such as ADP and 5HT from dense bodies. Phospholipid rich 
membrane, previously internalised in the platelet canalicular system, is 
exposed on the surface and increases the area upon which coagulation 
activation can occur.
There are three main intracellular signalling pathways (Wu, 1996).
1. The phospholipase C pathway is activated following G protein receptor 
signal transduction. This enzyme catalyses the hydrolysis of 
phosphatidylinositol biphosphate to produce two second messengers: 
Firstly inositol triphosphate (IP3) which causes an increase in 
cytoplasmic Ca^  ^by release from the dense tubular system. Calcium is 
involved in numerous processes involved in platelet activation, 
including cell contraction via actin and myosin and production of 
arachidonic acid. Secondly diacylglycerol induces protein 
phosphorylation necessary for platelet activation by activation of 
protein kinase C.
2. Adenylate cyclase activity is inhibited by an inhibitory G protein (Gi) 
that is coupled to the thrombin receptor. This leads to a reduction in 
intracellular cyclical Adenosine Monophosphate (cAMP) levels, which 
results in a further increase in intracellular Ca^  ^ and potentiates platelet 
activation.
3. Phospholipase A 2 activity is stimulated by increased cytosolar Ca^  ^and 
activation of protein kinase C. This enzyme cleaves arachidonic acid 
(AA) from platelet membrane phospholipid. This is converted to
7prostaglandin H; by the action of cyclo-oygenase which in turn is 
converted to thromboxane A; (TXA^) by thromboxane synthetase. 
TXA2 enhances platelet activation by reducing cAMP levels. It is 
rapidly metabolised in serum to TXBj, which is excreted in the urine.
• Platelet aggregation. Conformational change in surface membrane GPIIIa 
occurs on platelet activation, leading to increased surface density of these 
ligands and exposure of the fibrinogen binding site. Aggregates are formed 
when neighbouring platelet GPIIbllla complexes are crosslinked by fibrinogen 
andvW F (Nurden, 1995).
Assessment o f  platelet activation
There are therefore numerous ways in which platelet activation in patients can be 
assessed. There are advantages and disadvantages associated with each method, 
which will be discussed in chapters two and three. These are summarised in table 
1.1. Plasma markers o f platelet activation are relatively easy to assay by enzyme 
linked immunoassay (ELISA), but may be difficult to interpret since they are 
prone to artefact, given that ex vivo platelet activation might arise at the time of 
sampling or after centrifugation. Similar difficulties are encountered when 
preparing platelet rich plasma for aggregometry (Michelson 1996). This can be 
overcome by measuring urinary metabolites of TXA^, but although a 24 hour 
urine sample may yield information regarding in vivo platelet activation, it is a 
more indirect assessment of platelet function. Whole blood flow cytometry 
directly assesses platelet activation by P-Selectin expression and GPIIbllla
fibrinogen binding and avoids these problems, but has the disadvantage that 
samples must be processed and analysed immediately.
1.4 Platelet membrane glycoproteins.
As discussed above platelet glycoproteins are transmembrane molecules that are 
important in the process of clot formation. They exist in non-covalent association 
with other GPs to form heterodimeric complexes, and have two distinct roles in 
platelet activation and aggregation:
1. ‘Inside~out’ ligand binding. GP complexes bind to specific proteins which 
mediate interactions on the platelet membrane surface which promote clot 
formation. For example GPIb binds vWF, which is important in facilitating the 
adhesion of platelets to the vessel wall under conditions of high shear stress, as 
are found in arteries narrowed by atherosclerosis.
2. ‘Outside-in ’ receptor signalling. GPs function as receptors for agonists, and 
via signal transduction by G-proteins on the internal membrane surface, 
generate second messengers which mediate intracellular events leading to 
activation.
Specific GP complexes are discussed overleaf (summarised in Nurden, 1995):
1.4.1 GPIbIX
This complex mediates initial platelet tethering to the vessels via vWF. 
Glycoprotein Ib consists of two chains, a large a-chain o f 154kDa and a shorter 
22kDa B-chain which are linked by a disulphide bond. These chains are rich in
leucine residues, a feature shared with GPIX. The vWF binding region is located 
on the outermost extracellular part of GPIba, and lies somewhere between 
position 235 and 279. A high affinity receptor for thrombin has also been 
identified on Iba, although its function is unclear (Katagiri et al, 1990). Although 
the binding sequences are found on the a  chain, it is speculated that interaction 
with the B chain and GPIX occurs via leucine rich regions, and that these 
influence the avidity o f vWF binding.
1.4.2 G PM Ia
This complex mediates further platelet tethering by binding to type I and type III 
collagen, and promotes platelet activation by outside-in receptor signalling via the 
pathways described above. It has been demonstrated that the ability of platelets to 
bind collagen is dependent on surface receptor density (Kunicki et al, 1993).
1.4.3 GPIIbllla
The GPIIbllla complex in the resting platelet is mainly internalised in the internal 
canalicular system, but on platelet activation is translocated to the surface and 
undergoes conformational change which mediates platelet aggregation by 
fibrinogen binding. The genes for both GPIIb and GPIIIa are found very close to 
each other in the long arm of chromosome 17, and the two proteins are packaged 
together in the endoplasmic reticulum prior to transport o f the heterodimer to the 
surface membrane (Nurden, 1995).
GPIIb consists of a heavy (115kDa) and a light (22kDa) chain linked by a 
disulphide bridge. The latter is tethered to the platelet membrane, while the
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former protrudes form the platelet surface and interacts with GPIIIa. This occurs 
via a series of dodecapeptide repeat sequences which contain Ca^ + binding sites, 
and are important in divalent Ilbllla bonding. GPIIIa is a short (90kDa) single 
chain polypeptide that is characterised by numerous cysteine residues, which 
confer a tight globular structure by disulphide linking. Binding o f fibrinogen and 
other ligands such as fibronectin and vitronectin is mediated by RGD peptides 
(arg-gly-asp), the principal site being located between residues 109-171 of GPIIIa, 
and aggregation is mediated by the association of a dodecapeptide sequence the 
fibrinogen with the Ca^  ^binding region o f GPIIb on an adjacent platelet.
1.5 Risk factors for atherothrombotic stroke.
Arterial thrombosis has a multifactorial aetiology, and arises due to a complex 
interaction between genetic and environmental risk factors (Ridker & Stampfer, 
1999a). Conditions or behaviours which influence the processes o f atherogenesis 
or thrombosis might therefore increase the risk of stroke. Standard risk factors for 
stroke are summarised in table 1,2 (Rosendaal, 1997a). In most cases an effect on 
atherogenesis or thrombosis can be inferred. For example, cigarette smoking is 
associated with endothelial dysfunction and atherogenesis, as well as platelet 
activation and thrombosis (Powell, 1998). Similarly raised plasma cholesterol can 
be envisioned to contribute to lipid accumulation in the plaque lesion, and LDL 
cholesterol is involved in numerous stages o f atherogenesis following ingestion 
and modification by macrophages (Berliner et al, 1997).
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1.6 Polymorphisms of factors involved in thrombosis as 
candidate risk factors for stroke and myocardial 
infarction.
A family history of atheromatous disease is associated with an increased risk of 
stroke (Kiely et al, 1993) and although there may be common shared 
environmental risk factors within families, twin studies indicate that there is also a 
genetic component (Brass et al, 1992). CADASIL (cerebral autosomal (dominant 
arteriopathy with .subcortical mfarcts and /eucoencephalopathy) is a condition 
arising from a gene defect on chromosome 19ql2 which results in a Mendelian 
inheritance o f stroke, but this is very rare (Pullicino et al, 1997). Polymorphisms 
are gene mutations more commonly found in the population. These are usually 
the result of single nucleotide substitutions, or variation in the number of tandem 
repeat sequences (VNTRs) in a non-coding region (intron) o f the gene. The effect 
of a polymorphism on gene function may be subtle or neutral, but some may 
contribute to disease pathogenesis.
Numerous polymorphisms have been studied, and those potentially involved in 
thrombosis are listed in table 1.3. Case control studies have attempted to 
associate these with disease by demonstrating greater allele frequencies in 
survivors o f myocardial infarction and stroke than healthy controls, but consistent 
associations are often not apparent.
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Factor V Leiden
With this mutation the substitution of adenine for guanine at position 1691 leads 
to the substitution of arginine by glutamine on position 506 of the amino acid 
chain. This mediates thrombosis by rendering Factor Va resistant to cleavage by 
activated Protein C (Bertina et al, 1994). This mutation might be viewed as the 
‘gold standard’ in studies of genetic polymorphisms and thrombosis, since there is 
both epidemiological evidence of risk in venous thrombosis and a convincing 
functional explanation for how this is mediated.
Despite these observations, the role o f Factor V Leiden in thrombotic stroke and 
MI is less clear. Studies are summarised in table 1.4. Only two have found an 
association with MI, and none with stroke. Rosendaal et al (1997b) observed a 
doubling of risk o f MI in those possessing the 1691A allele, in a small study of 84 
young women. The relative risk rose to 3,6 in the 69 who also smoked, 
suggesting that genetic and environmental factors might interact. However 
caution was advocated in interpreting these data since the small sample size did 
not provide adequate statistical power to fully investigate such relationships. 
These preliminary observations were supported by a larger study of 560 survivors 
of MI, where a substantial increase in risk was also reported in those who smoked 
(Doggen et al, 1998a). However in a cohort of 2210 patients these findings were 
not reproduced in neither patients with stable coronary artery disease nor acute MI 
(Gardemann et al, 1999). No association was observed in 386 older patients with 
acute stroke, nor was the G allele associated with enhanced thrombogenicity 
(Catto et al, 1995). This study included patients with all subtypes of stroke, 
including haemorrhage, and it could be speculated that an effect might be
13
restricted to those with thrombosis. Several other studies demonstrated the 
mutation was not a risk factor for stroke or myocardial infarction in any subgroup 
(Ridker et al, 1995; Cushman et al, 1998; Longstreth et al, 1998; Ardissino et al, 
1999; Gowda et al, 2000).
G202Î0A prothrombin gene mutation
This single base substitution arises in the 3’ end of the prothrombin gene and the 
A allele is associated with enhanced thrombogenicity and increased risk o f venous 
thrombosis, possibly as a result o f the observed increase in plasma prothrombin 
concentrations (Poort et al, 1996). Clinical studies of arterial disease are 
summarised in table 1,5, and are again conflicting despite the mutation producing 
a plausible prothrombotic phenotype. Rosendaal et al (1997c) reported a fourfold 
increased risk o f MI in 79 young women, with a relative risk o f 43 in smokers. A 
similar risk was observed in young patients with ischaemic stroke (De Stefano et 
al, 1998). The size of these studies necessitates caution when interpreting their 
significance, and others have yielded conflicting results (Corral et al, 1997a; 
Ferraresi et al, 1997; Eikelboom et al, 1998; Longstreth et al, 1998; Arruda et al, 
1998; Ardissino et al, 1999; Franco et al, 1999; Ridker et al, 1999b). A study of 
263 young patients with ischaemic heart disease demonstrated that, despite the A 
allele being associated with greater prothrombin concentrations, their was no 
statistically significant association of the polymorphism with arterial disease 
(Franco et al, 1999).
The dissociation between prothrombotic phenotype and MI or stroke has led some 
to suggest that the influence of a single gene on stroke pathogenesis is small, and
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only results in a clinically significant effect when there is interaction with 
environmental or other genetic risk factors. This view is supported by a large 
study of patients with MI, where an interaction between the prothrombin gene 
mutation and smoking was observed (Doggen et al, 1999a). Gardemann et al 
(1999) reported no association with MI or stable coronary disease, but noted that 
the extent of stable disease (determined angiographically) was influenced by 
genotype in those who possessed other risk factors. However there was no 
evidence of such an interaction influencing the risk of acute coronary thrombosis.
Thus despite evidence o f a plausible prothrombotic effect o f a polymorphism and 
clear evidence of risk in venpus thrombosis, neither factor V Leiden nor the 
prothrombin mutation are consistent independent risk factors for stroke .
Fibrinogen gene polymorphisms
Similar inconsistencies have been observed in studies o f fibrinogen gene 
polymorphisms {table 1.6). Possession of the A allele of the -455 G/A 
polymorphism in the promoter region of the fi gene is associated with higher basal 
plasma fibrinogen concentrations in most studies. Despite this, and although a 
higher plasma fibrinogen concentration is itself an independent risk factor, 
associations of the A allele with IHD and MI are inconsistent (Behague et al, 
1996; Yu et al, 1996; Carter et al, 1996; Wang et al, 1997; Gardemann et al, 
1997; Tybjaerg-Hansen et al, 1997; de Maat et al, 1998). The Bel 1 13-gene 
polymorphism does not increase baseline risk, but was observed to amplify the 
acute phase response and increase the risk of myocardial infarction in subjects 
with systemic infection (Zito et al, 1999). This was a small study and possible
15
interactions between gene and environment require further exploration in larger 
studies.
There are fewer data regarding the risk of stroke. The -455A allele conferred a 
doubling of risk in a small study of Japanese patients (Nishiuma et al, 1998), but 
did not influence plasma fibrinogen in this cohort. Others have observed an 
association with stroke, but the study included all stroke subtypes and the 
association was only found in women (Carter et al, 1997a). Carter et al (1999) 
did not observe an association between stroke and the Thr312Ala alpha gene 
polymorphism, but reported shortened survival in the 101 patients who also had 
atrial fibrillation. Caution in interpreting these observations is necessary since 
subgroup analyses of modest numbers of patients were performed, and 
reproduction o f these data in other populations is desirable. The Austrian Stroke 
Prevention Study identified homozygosity for the T allele o f the C148T 
polymorphism within the interleukin-6 responsive element o f the B gene as an 
independent risk factor for carotid atherosclerosis, despite there being no 
correlation between plasma fibrinogen and genotype (Schmidt et al, 1998).
The lack of association in most studies between genotype and arterial thrombosis, 
despite an association with fibrinogen level, weakens the proposal that fibrinogen 
is a causative risk factor for stroke, and. it could be suggested that levels are 
merely a marker of the systemic inflammatory response observed in individuals 
with atherosclerosis.
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Other polymorphisms
Platelet glycoprotein, MTHFR and factor VII polymorphisms are discussed in 
subsequent chapters. Polymorphisms of the plasminogen activator inhibitor-1 
(PAI-1) gene have been studied {table 1.7), since elevated plasma levels are 
associated with MI, and might promote a prothrombotic state by inhibiting 
fibrinolysis. Despite demonstration of the influence of genotype on plasma PAI-1 
concentrations, reports are again conflicting and associations are only found in 
certain subgroups of the patient cohort in some studies (Dawson et al, 1991; 
Mansfield et al, 1995; Eriksson et al, 1995; Ye ef al, 1995; Ridker et al, 1997; 
Catto et al, 1997; Ossei-Geming et al, 1997; Iwai et al ,1998; Doggen et al, 1999; 
Gardemann et al, 1999; lacoviello et al, 1998a).
There are few reports of the Val34Leu polymorphism of Factor XIII, but the allele 
coding for Leu was found to be underrepresented in subjects with coronary artery 
disease who subsequently developed acute MI (Kohler et al, 1998), and it was 
suggested that the mutation might be protective against MI. One other study 
supports these observations (Wartiovaara et al, 1999). Confirmation in other 
populations is required, but these preliminary findings are supported by the 
obervation that the ‘protective’ allele increases the risk of primary intracerebral 
haemorrhage in a study of all subtypes of stroke (Catto et al, 1998), possibly as a 
result o f impaired fibrin clot stability.
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1.7 Conclusions and outline of studies undertaken in this 
thesis.
The role of haemostatic gene polymorphisms is clearly more difficult to elucidate 
in arterial disease than in venous thrombosis due to the more complex 
pathogenesis, and associations are less easy to demonstrate. The main 
conclusions drawn from this literature review, and the studies undertaken to 
further investigate these points are listed below:
1) Candidate genes should have a plausible effect on haemostatic function to 
support a role as a risk factor.
Polymorphisms o f platelet glycoprotein receptors are such candidates. As will be 
discussed, and in common with the candidate genes discussed above, 
epidemiological data are conflicting and there are no consistent functional data to 
support these polymorphisms as risk factors for stroke. In Chapter three the HPA 
la /lb  polymorphism of GPIIIa was studied in healthy subjects, and a correlation 
between platelet genotype and function was sought. In chapter four this approach 
was extended to the setting of an acute thrombotic event. Platelet activation status 
was measured in patients in the acute and convalescent periods of 
atherothrombotic stroke. This was related to HPA la /lb  and HPA 2a/2b 
(polymorphism of GPIb) genotypes in order to provide a functional assessment of 
these risk factors.
2) Even in instances where a plausible mechanism is demonstrated, many 
epidemiological studies fail to confirm the candidate gene as a risk factor for 
stroke or MI.
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This was observed in the case of B-fibrinogen polymorphisms. Despite 
demonstration o f increased plasma fibrinogen levels, the -455A allele was not an 
independent risk factor for arterial disease, and the causative role o f a raised 
fibrinogen concentration could therefore be challenged. Similarly, as will be 
discussed in chapter five, the MTHFR polymorphism results in an increases in 
plasma homocysteine concentration and, although increased levels independently 
increase the risk of MI and stroke, MTHFR genotype itself does not. The role of 
mild hyperhomocysteinaemia as a cause of atherothrombotic stroke is therefore 
unclear. Fasting concentrations were measured in the study cohort immediately 
after stroke, and in those who reattended at least three months later. These were 
compared with age and sex matched controls, and the influence o f factors known 
to increase homocysteine concentrations was investigated.
3) Some polymorphisms might be protective against stroke or MI.
The suggestion that some polymorphisms reduce the risk of stroke (and MI) was 
tested in chapter six. Alleles of factor VII gene polymorphisms that are associated 
with reduced factor VII concentrations and are claimed to be protective against 
MI were elucidated in a population o f extremely elderly people. The hypothesis 
that these alleles contribute to longevity by facilitating the avoidance of arterial 
events was tested, by comparing allele frequencies with a younger control group.
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50% Proximal 
Artery Thrombus
50% Cardiac 
Thrombus
Thromboembolic
85% Cerebral 
Infarction
Local
Atherothrombosis
Stroke
15% Haemorrhagic
figure l .L  Pathophysiology of stroke.
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Method Advantage Disadvantage
Plasma P-Selectin Simple Ex vivo activation 
Indirect method
Plasma B-TG Simple Ex vivo activation 
Indirect
Plasma TXAg Simple Unstable in plasma
Urinary TXB or B-TG Stable, not subject to ex 
vivo influences
Indirect assessment of 
platelet function
Aggregometry Direct assessment of 
platelets
Ex vivo activation
Flow cytometry of 
platelet rich plasma.
Direct assessment of 
platelets
Ex vivo activation
Whole blood flow 
cytometry
Direct method 
No vivo activation
Labour intensive 
Must be done immediately
Table l .L  Methods available for assessment of platelet activation.
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Risk factors for cerebral infarction
Hypertension 
Smoking 
Diabetes Mellitus 
Hypercholesterolaemia 
Family History 
Obesity 
Oral Contraceptives 
Hyperhomocysteinaemia 
Antiphospholipid syndrome 
High plasma Fibrinogen concentration
Table 1.2, Risk factors for thrombotic stroke.
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Candidate polymorphisms
Factor V Leiden 
Factor II G20210A 
Fibrinogen gene polymorphisms 
Polymorphisms of platelet membrane GPIb, Ilia and lalla 
Factor VII polymorphisms 
MTHFR C677T polymorphism 
PAI-1 4G/5G polymorphism 
_____________ Factor XIII polymorphisms_____________
Table 1.3. Polymorphisms of factors involved in thrombosis 
investigated in stroke and myocardial infarction.
I
I
»
<
II
I
I
ga
IIII^ 1»
'Os iI
I
i
& z  zo  oi s pII
it
1 1
1—1 fHg|
I
O)
&
i l s
Î1Î
Î
S '
ÎI
:9<D
% S '
if§1
to1/1
1 1I
Q
I
VO g
VO CA00
a>
s
g
g s
3 3
Ui to
If
5?'-j n
I
CO
E#
II
Z  5 ‘
N)  ^\0 l/i
Ï Ï
4 ^  VO
^  S’
I
I Ï
S '8,IT
I Iera CD
^  c5
II
era Mn h>
(3 ^ K
i  §" I
l i t
p ,  -
oi s'
1 .15 s  }=b era
il
I
IIt
s  s
o
oo o
" S ’s
w
itlOQ w o
i
I5?>
mS oII!
§##
11*
S"
s- 3.
l i s
B-'^
e- ^
II > %
t l
H- OnLh U)
îi'
ÎSuivo =o 
8&
I  g
M
s-3
i§
> 00
k
| i
II
m| | r
II
I I
1^
I s .
8^ o
I f
00
5-
il
;a
I!
3.
Hr
trj 
^  0
O  MO
ç^ü>
t
a
P
K
il
Ii
I K)l/i
IÏ
S
s1-Ü
<
gI
t/l
i
GO
OV 03
s?
Ii
If
ë >II
5-
I &
îi
S- o
II
l î
0  p
i!
1
D
I i
ff
p-
S
h3
lîn 09
s S
A B
B
LAOn 0t/i 00 p00 3U)
O
O.
SI
l . i f
T
O
îil/l l/l
Î-B
CD O
o-'S
S
§?
II.
Îi
II
§
CD
II
H
%
1 1
a l f
o  or
<  % Q 41-
t ’S
ÎI
H
I
en 4
S ,
D- O
fi
fls  < 3n  l/l
W
OS
I
N
GO
I
s,
i
II
s,
f
■g
I3
K
I
KJ LO
p 1/1 LO
15 : it s
eg
tn> %
II
2,
II O 4^:"Q4^
^  3 . 3  o
& ^ II
S '  g .
II
« s
I?
i? “
rl
^  cr
5 -I  |§
I
 ^2. 
a 
s.
2, o
il
II
s*
it
Ï Ï
î l
m
gL2,{R
I  § 
§
bo <3 
'w '4i. U» ^
2, I
2,%
î i
I
i i(D
A OvU) 4i^ 1/11/1Os ov
foo L
3 3
e 1:)
? IQ.
1 ?eu
1 a*cr
B a
s ss oGt fttfO
S so o
1 §cu
M
CO
e - s
i l" 0)LA
H-00 On
Is.
00
if
hj 4=i.
"iIIs.
I
tr
f
Ï
O §
i l la> o '' CO
S|e o
K)
Chapter Two
Patient and volunteer recruitment, sample 
handling and characteristics.
29
2.1 Platelet donor study (Chapter 3).
Platelet and plasma donors attending the North East of Scotland Blood Transfusion 
Service apheresis unit of known HPA la /lb  genotype were approached. This had 
previously been determined by the polymerase chain reaction with sequence-specific 
priming (Cavanagh et al, 1997) in a study investigating the incidence o f neonatal 
alloimmune thrombocytopenia (NAITP) in the Grampian region o f Scotland. This 
PCR-SSP technique is described in chapter four. Prior to donation written informed 
consent was obtained, and blood samples taken from resting subjects who had been 
supine for at least five minutes. Donors had a large (16G) apheresis needle inserted 
into an antecubital vein with a cuff applied to the upper arm. Care was taken to avoid 
artefactual platelet activation: venepuncture was performed in supine subjects 
following at least ten minutes rest; minimal stasis was applied and the tourniquet 
removed following the free flow of blood into a syringe. The first five ml of blood 
was discarded, and the whole sample was rejected if  resistance to flow or air bubbles 
in the syringe were encountered. At the bedside 9ml whole blood were added to 1ml 
of 3.2 % trisodium citrate in a universal container. A 50ql aliquot was immediately 
mixed with 450pl of HEPES-magnesium buffer. All samples were subsequently 
processed within two hours of sampling.
Thirty five subjects possessing the lb  allele (34 heterozygotes and 1 homozygote) 
were compared with 35 subjects homozygous for the la  allele. All subjects were 
healthy, with no history o f symptomatic CVA, ischaemic heart disease, or use of 
aspirin or other drugs affecting platelet function.
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2.2 Stroke Study patients and controls (Chapters 4 and 5)
2.2.1 Recruitment
Consecutive patients admitted to Aberdeen Royal Infirmary within 24 hours (up to 96 
hours) of the onset of symptoms of stroke were assessed for eligibility between June 
1997 and December 1998. This is the sole primary referral centre for the Grampian 
region of Scotland (population approximately 600 000); patients are therefore 
representative of the general stroke population. The study was approved by the 
Grampian Regional Ethical Committee. In an attempt to study a single pathological 
cause of stroke patients with a history of atrial fibrillation or valvular heart disease 
were not approached. Stroke was defined as a sudden loss of global or focal cerebral 
function which persisted for more than 24 hours. Patients were approached on 
admission and formal written consent obtained. A computerised tomographic (CT) 
brain scan was performed on all patients, and those with evidence of intracranial 
haemorrhage or o f alternative intracranial pathology were excluded. In order to study 
only probable atherothrombotic stroke, a subsequent clinical assessment was made to 
exclude a previously undetected cardioembolic pathogenesis. Patients with evidence 
of valvular heart disease or thrombus on echocardiography, and those in, or who 
subsequently developed, atrial fibrillation were excluded. Those considered to have 
suffered a transient ischaemic attack (TIA, symptoms resolving within 24 hours) were 
included, provided that a cardiac source of embolus was considered unlikely based on 
the clinical assessment. Additional diagnoses and drug therapies were recorded, and 
patients with a past history of a connective tissue disease or those taking oral 
anticoagulants were not recruited. Duplex ultrasound examinations were performed 
to identify evidence of carotid atheroma. Age and sex matched controls were 
obtained from a local general practice, which cares for a population from a large area
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of the City of Aberdeen, and consists of a similar racial and social class mix to the 
patient cohort. Those bom in the same year as subjects with no history of stroke, 
TIA, or peripheral vascular or ischaemic heart disease were recmited after written 
informed consent.
The distribution of clinical risk factors, fasting lipid measurements and 
haematological variables in patients and controls were recorded. A diagnosis of 
hypertension, diabetes mellitus or hyperlipidaemia was defined as receiving current 
treatment for, or a past history of the condition. A family history was defined as an 
arterial thrombotic event in a first degree relative before the age of 55 years.
It was calculated that 150 subjects and 150 controls were required to detect a twofold 
difference in HPA lb  allele frequencies between cases and controls with 80% 
statistical power, assuming a control frequency of 19% based on published 
frequencies (Weiss et al, 1996). It was intended to select as young a cohort as 
possible to amplify any genetic effect on stroke risk, and a study of admissions to 
hospital with stroke in the preceding five months was performed. The number of 
admissions for the following 18 month period was estimated, and it appeared that 
selection of patients younger than 60 years would allow recruitment o f the desired 
cohort size in this time (figure2.1). However in January 1998 the arbitrary cut-off age 
had to be increased to 70 years to permit recmitment the desired number of subjects 
in the given time, since the initial estimate did not account for the exclusion criteria 
described above.
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2.2.2 Sampling fo r  platelet flow  cytometry and genotyping
A  sample was obtained from patients and controls using a large (21G) butterfly 
needle. The method o f venepuncture to ensure minimal ex vivo platelet activation 
was as described above for donors. Additional blood was obtained for leucocyte 
DNA extraction, full blood count, plasma fibrinogen concentration, and fasting 
cholesterol concentrations.
Patients were invited to reattend by letter for repeat sampling in the convalescent 
period, at least three months after the acute event. In those who agreed repeat 
measurements of platelet activation status and plasma fibrinogen concentration were 
obtained, and the use o f antiplatelet drugs was recorded. In order to avoid selection 
of those with mild stroke only (who were able to attend the clinic), patients in 
residential care or in long-term rehabilitation were visited at their place o f residence 
for sampling.
2.2.3 Sampling fo r  plasma homocysteine measurement.
4.5 ml blood samples were taken between 7am and 9am following an overnight fast, 
into Vacutainer tubes containing EOT A (Becton Dickinson, Cedex, France). EDTA 
is preferable to citrate as it inhibits reoxidation of samples following the reduction 
step of preparation (Ueland et al, 1993). These were taken immediately to the 
laboratory and the plasma separated. In order to avoid release of Hey from cellular 
elements all samples were centrifuged within one hour of collection, as this is 
associated with minimal spurious increases in plasma Hey (Ueland et al, 1993). 
Plasma was stored at -70 °C until analysis. Additional samples were obtained for red 
cell folate and serum B12 assays, and for estimation of serum creatinine and fasting
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cholesterol concentrations. The use of medications associated with an increased 
plasma homocysteine was recorded.
Patients who reattended after three months also provided a fasting blood sample for 
convalescent plasma homocysteine measurement. A subgroup of patients provided 
samples for convalescent phase red cell folate, and serum B12 and creatinine 
estimations.
2.3 Results
2.3.1 Subjects
The outcome of patient recruitment is summarised in figures 2.2.and 2.3. 179
consecutive patients with CVA or TIA and no previous history o f valvular heart 
disease, atrial fibrillation or vasculitis consented to participate. 29 patients were 
subsequently excluded: ten with intracranial haemorrhage; seven with atrial 
fibrillation; four with cardiac thrombi or valvular heart disease; four with intracranial 
tumours; and four who were considered to have an alternative diagnosis to stroke. 
The mean age (range) of patients and controls was 58.3 years (25-70) and 56.9 (24- 
72) respectively. 77 (51.3%) patients were recruited within 24 hours of stroke onset, 
a further 53 (35.3%) within 48 hours, 15 (10%) within 72 hours, and the remaining 5 
(3.3%) within 96 hours. 140 patients (93.3%) were considered to have suffered a 
cerebral infarction and 10 (6.7%) a TIA. 109/150 patients (72.7%) had a carotid scan. 
Of these 42 (38.5%) had evidence of carotid atheroma. The mean time to follow up 
was 100.3 days (range 68-270), and by May 2000 15 patients had died.
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HPA la /lb  and HPA 2a/2b genotypes of 150 cases (52 male/98 female) and 150 
controls (52 male/98 female) were determined. Platelet activation was assessed in all 
patients and in 112 controls (52 male/60 female). 77 (48 male/29 female) patients 
provided a repeat sample for platelet activation markers in the convalescent period.
Measurements o f fasting tHcy concentrations were obtained in 106 age and sex 
matched controls. Since tHcy is age and sex dependent (Selhub et al, 1996), the 44 
patients for whom a control was unavailable were also excluded to ensure the cohorts 
were closely matched, and males and females were analysed separately. The mean 
age (range) of male patients and controls was 57.2 (25-70) years and 56.7 (24-72) 
respectively, and in females 56.5 (26-69) and 56.5 (30-71) respectively. Fifty six 
(52.8%) patients were recruited within 24 hours, 33 (31.1%) within 48 hours, 13 
(12.3%) within 72 hours and the remaining 4 (3.8%) within 96 hours o f the onset of 
symptoms. 96 (90.6%) patients were considered to have suffered a cerebral 
infarction, and 10 (9.4%) a TIA. 83/106 (78.3%) had a carotid scan performed. Of 
these, 28 (34%) had evidence of carotid atheroma. 82 patients provided a fasting 
sample in the convalescent period. Data were not available on the remaining 24 
patients, since they either refused to provide a convalescent sample or had died.
The mortality rate in the study population studied is low, which might reflect that the 
majority of patients were admitted to an acute stroke unit with resultant improved 
survival (Diez-Tejedor and Fuentes, 2001), or this may be a chance observation. The 
possibility of recruiting less severely affected patients is unlikely given that 
consecutive patients admitted to hospital were included. This potential bias was also
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corrected for in the follow up phase, by resampling those unable to attend hospital as 
described above.
2.3.2 Conventional risk factors
Personal risk factors for ischaemic stroke and routine laboratory variables in the study 
of platelet function are summarised in table 2.1. Comparisons between patients and 
controls matched for the study of homocysteine yielded very similar observations 
(data not shown). Current smoking and hypertension were confirmed as risk factors 
for atherothrombotic stroke, but the odds ratios for diabetes mellitus and a positive 
family history did not reach statistical significance. Neither a history o f treatment for 
hyperlipidaemia, nor fasting total, LDL cholesterol, nor triglyceride concentrations 
were associated with stroke. However an apparent protective effect of HDL 
cholesterol was detected, the mean concentration being significantly greater in 
controls (p<0.001). The mean acute phase plasma fibrinogen concentration {SD} was 
significantly higher than in controls (4.3{l.l}g/l vs 3.3{0.9}, p<0.001, Student’s t- 
test), and this difference persisted into the convalescent phase (4.1 {1.1} vs 3.3 {0.9}, 
p<0.001). In patients who attended for follow up the mean fibrinogen concentration 
was higher immediately after stroke than in the convalescent period, but this 
difference did not reach statistical significance (4.3{1.0}g/l vs 4.1 {1.0}g/l, p=0.06 
paired t- test). Acute phase fibrinogen concentration correlated with that on follow up 
(r^=0.493, p<0.001). There was no statistically significant difference in mean platelet 
count nor mean platelet volumes in acute and convalescent phases, nor between 
patients and controls (table 2,1).
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The lack of an association between serum total cholesterol or LDL and stroke may 
reflect a fall in concentrations following the acute event, possibly as a result of poor 
nutrition in this period (Butteiworth et al, 1997). This observation also supports the 
suggestion that the study included patients with severe stroke, since a reduced 
cholesterol concentration measured within 24 hours of ictus is been associated with 
reduced survival (Dyker et al, 1997).
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Figure 2.1 Admissions with stroke to Aberdeen 
Royal Infirmary 11/01/97-12/06/97.
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Chapter Three
An investigation of the effect of HP A 
la/lb genotype on platelet fibrinogen 
binding by whole blood flow cytometry in
healthy subjects.
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3.1 Background
As discussed in chapter one, genetic factors might contribute to the risk of stroke, and 
it has been postulated that polymorphisms of platelet surface membrane 
glycoproteins (GP), by an effect on platelet function might be involved. GPIIIa, in 
heterodimeric complex with GPIIb, is central in the process o f platelet aggregation 
which is mediated mainly by fibrinogen binding (Nurden, 1995). The HP A lb (PIA^) 
allele of the la /lb  (PIA/A^) polymorphism arises due to a substitution of thymine by 
cytosine at position 1565 in exon 2 of the human GPIIIa gene. This results in the 
replacement o f leucine by proline at amino acid 33 of the protein (Newman et al, 
1989). HP A lb  is common, being present in around 25% of Northern Europeans 
(Bray, 1999), and has been widely investigated as a candidate risk factor for arterial 
thrombosis. Studies have failed to consistently link the Ib allele with ischaemic 
stroke (Ridker et al, 1997c; Carter et al, 1998), but an association in younger patients 
has been proposed (Carter et al, 1998; Wagner et al, 1998). Some case control 
studies (Weiss et al, 1996; Carter et al, 1997b; Gardemann et al, 1998; Garcia-Ribes 
et al, 1998; Mikkelsson et al, 1999), but not others (Marian et al, 1996; Osbom et al, 
1996; Herrmann et al, 1997; Ridker et al, 1997c; Samani & Lodwick, 1997; Durante- 
Mangoni et al, 1998) have associated the lb  allele with increased risk o f Ml.
The plausibility of any relationship between this candidate gene and thrombosis is 
dependent upon evidence of altered platelet reactivity associated with individual 
alleles, and interpretation of these conflicting epidemiological data is hindered by a 
lack of corresponding functional data in most studies. Although the polymorphism is
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some distance from the fibrinogen binding sites on GPIIIa (positions 109-171 and 
211-222), it has been proposed that the lb  allele might alter fibrinogen binding, 
which in turn might influence platelet aggregation (Bray, 1999). In addition to its 
function as a ligand ( ‘inside-out’ signalling), GPIIIa is also involved in ‘outside-in’ 
signalling, where platelet activation by receptor mediated intracellular signalling 
follows the binding of fibrinogen and vWF to GPIIIa (Shattil, 1999). Thus 
thrombotic risk might be postulated to arise as a result o f enhanced platelet activation 
mediated by the lb  allele, but at the time o f this study a plausible prothrombotic 
mechanism had not been described to support the lb  allele as a risk factor for 
thrombosis.
3.2 Aims
An effect o f the HP A lb allele on platelet function was sought in healthy subjects. 
This was explored by whole blood flow cytometry to investigate ‘inside-out’ 
fibrinogen binding directly, since this permits the direct study of the interaction of 
fibrinogen with its receptor, and obviates the artefactual effects encountered in 
aggregometry (Michelson, 1996). The influence of genotype on fibrinogen binding at 
rest and following stimulation with the weak agonist adenosine diphosphate (ADP), 
was determined. In addition, platelet P-Selectin expression was investigated as a 
reflection of ‘outside-in’ receptor signalling, and an allele dependent effect was 
sought.
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3.3 Methods
2.3.2 Detection o f  platelet activation markers by whole blood 
fluorescence activated cell sorting (FACS)
Detection o f platelet activation markers by FACS 
Platelet surface binding of fibrinogen was assessed by single colour technique using 
FITC conjugated polyclonal rabbit antihuman fibrinogen antibody, which is not 
affected by non-specific platelet fibrinogen binding or plasma fibrinogen 
concentration (Warkentin et al, 1990).
The technique can be summarised thus:
• Platelets are identified by light scatter characteristics and by FITC conjugated 
antiCD61 (GPIIIa).
• Fibrinogen binding is analysed using single colour analysis with FITC conjugated 
antifibrinogen.
• Basal activation status is assessed in resting platelets (no added agonist).
• Platelet reactivity is assessed by analysis of samples preincubated with ADP (a 
weak agonist).
• P-Selectin expression is analysed by dual staining with FITC-antiGPlIla and PE 
conjugated anti-P Selectin (CD62P).
Sample preparation
Subsequent reactions were performed in a standardised manner. 40pl aliquots of 
whole blood in HEPES were incubated in polypropylene tubes for 30 minutes at 
room temperature in the dark with 10 pi monoclonal antibody. Antibodies were
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diluted to yield a final optimal concentration of 2ng/pl in each reaction. This was 
determined by individual manufacturer’s recommendations and had been previously 
validated in the laboratory. Aliquots from each subject were subject to seven 
separate reactions as described below:
Tube 1: FITC-mouse IgG isotype control (Becton Dickinson Ltd, California USA).
Tube 2: PE-mouse IgG isotype control (Becton Dickinson Ltd, California, USA).
Tube 3: FITC- murine antihuman GPIIIA (CD61) (Dako Ltd, Glostrup, Denmark) to 
identify platelets.
Tube 4: FITC-murine antiCDbl (Dako) and PE-murine antiP-Selectin (CD62P) dual 
staining to assess basal P-Selectin expression.
Tube 5: As tube 4, preincubated for 5 minutes with 5 pi PMA (final concentration 
Ipg/ml, Sigma, St Louis, USA) as positive control.
Tube 6: FITC-rabbit polyclonal antihuman fibrinogen (Dako Ltd, Glostrup,
Denmark) to assess basal fibrinogen binding.
Tube 7: As tube 6, preincubated with 5 pi ADP (Sigma Chemical Co, St Louis, 
USA), at a final concentration of lO’^ M to assess fibrinogen binding after 
platelet activation.
Reactions were stopped by the addition of 2ml phosphate buffered saline (PBS), and 
samples stored at 4°C  until FACS analysis. Samples were analysed within three 
hours of processing.
FACS analysis
The study was performed using a Coulter XL-MCL flow cytometer (Coulter 
Electronics, Luton, UK). Numbered tubes were placed in an autoanalyser carousel.
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The sample was drawn into the analyser at the ‘low’ flow rate setting. Listmode data 
were stored and processed using a personal computer and System II software version 
1.0 (Coulter Electronics Ltd, Luton, UK), and converted to scatterplots and 
histograms. Cells were separated by their forward and side light scatter 
characteristics (determined by cell size and granularity respectively). Particles 
corresponding to platelets in the scatterplot (figure 3.1) were enclosed in an electronic 
bitmap and analysed for fluorescence following laser excitation at 488nm, FITC 
conjugated antibody emitting a 530nm signal (green) and PE a 585nm signal (red). 
Sampling was terminated automatically following accumulation of 10000 events, and 
the percentage o f positive platelets and mean cell fluorescence recorded.
Fibrinogen binding was assessed indirectly by first identifying the percentage of the 
events analysed which were platelets as defined by FITC-antiCD61 positivity in tube 
3. The percentage of events positive for FITC-antiflbrinogen at baseline in tube 6 
and following ADP stimulation in tube 7 (figure 3.2) was then adjusted for this value. 
This method has been previously validated (Janes et al, 1993). P-Selectin expression 
was recorded from events dual staining for anti-CD61 and anti-CD62P (figure 3.3).
Statistical analysis and sample size 
Calculations were performed using SPSS for Windows version 8.0 statistical 
software. Allele dependent differences in means were assessed by Student’s t-test for
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normally distributed data and medians were compared by Mann Whitney U-tests 
when data were skewed. The sex distribution of the two groups was compared by 
Fisher’s exact test. It was calculated that 35 subjects homozygous for HP A la /la  and 
35 possessing the lb  allele were required to detect with 80 % statistical power a 10% 
difference in fibrinogen binding after incubation with ADP. A two tailed p value of 
<0.05 was considered significant.
Quality assurance
A positive control sample {figure 3.4) was included to ensure the presence of reactive 
platelets, by assessing CD62P expression upon incubation with phorbol myristate 
(PMA, Sigma Chemical Co, St Louis, USA), which induces activation via the protein 
kinase C intracellular pathway (Michelson, 1996). Correction for non-specific 
binding of antibody to platelets was facilitated by the use o f idiotype antibodies 
(Dako, Glostrup, Denmark). Since almost all antibodies used were o f murine origin 
these were conjugated mouse IgG, antibodies with specificity for an antigen absent in 
humans.
The flow cytometer was aligned daily with ‘Flowcheck™’ and Tmmunobrite™’ 
beads (Coulter Electronics, Luton, UK) to calibrate light scatter and fluorescence 
parameters respectively. A laboratory log of these steps was recorded daily to ensure 
regular calibration. The flow cell was cleaned thoroughly between individual subject 
samples to exclude carry over of platelets to subsequent analysis using Coulter 
Clenz™ cleansing solution (Coulter Ltd, Luton, UK). Solutions were filtered prior to 
use to remove small particles of a similar size to platelets, and were renewed weekly.
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Aliquots of ADP and PMA were stored at -20 ° C prior to use, and it was determined 
that thawed aliquots of ADP should be used immediately, since use more than one 
hour after thawing resulted in a 10% reduction in stimulated fibrinogen binding (data 
not shown). PMA could be repeatedly thawed and refrozen, as this had no effect on 
the extent of CD62P expression.
The optimal dilutions o f each new batch of antibody were established by comparison 
with the working concentration of antibody from the previous batch. The isotype 
controls were used to correct for non specific platelet protein binding and the 
negative cut-off was set at 0% positivity. To avoid the influence o f artefactual 
platelet activation, data were normalised and samples yielding a % fibrinogen binding 
or CD62P value greater than three standard deviations from the mean were discarded, 
and the subject was resampled at the next donation visit.
3.4 Results
Results are summarised in table 3 J .  There was no allele dependent difference in the 
median percentage of platelets binding fibrinogen at baseline (p= 0.14, Mann 
Whitney U-test) nor in means following incubation with ADP (P=0.72, Student’s t~ 
test, see figure  3.5). The density of fibrinogen binding sites, as measured by mean 
cell fluorescence, was greater in la  than lb  platelets following stimulation with ADP 
(p=0.05 Mann Whitney U test). This is illustrated in figure 3.6. There was a 
tendency for more lb  platelets to express P-Selectin, but this did not achieve 
statistical significance (p=0.08, Mann Whitney U-test). No difference in CD62P 
mean cell fluorescence was observed (p=0.54, Mann-Whitney U test).
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There was no significant age difference between the two groups (mean age {range} 
42.2 years {27-60} in la /la  group, and 41 {25-56} in those possessing the lb  allele, 
p-0.6. Student’s ?-test), and no difference in sex distribution between the two groups 
was observed (26 male/9 female in la /la  versus 22 m ale/13 female in la /lb  and 
lb /lb  group, p=0.44, Fisher’s exact test). 5/70 subjects initially had baseline 
increased fibrinogen and/or P-Selectin expression suggestive o f ex vivo activation. In 
each case repeat sample collection yielded values within the normal range (not 
shown), and initial data were excluded from analysis.
Genotype % Fibrinogen 
median (range)
%Fibrinogen 
post ADP 
mean (SD)
Fibrinogen 
mean X post 
ADP
median (range)
% CD62P
median
(range)
CD62P 
mean X 
median (range)
la /la
la /lb  and 
lb /lb
Significance
0.7 (0.1-3.1) 
0.5 (0.2-2.4)
0.14'
59.9(13.8) 
58.7 (14.2)
0.72"
9.4 (4.7-20.3) 
7.2 (3.4-16.0)
0.05'
0.1 (0-0.7) 
0.25 (0-1.3)
0.08'
1.4 (0.95-2.16)
1.4 (0.94-2.18)
0.54'
Table 3.1 Results. The effect genotype on the percentage of platelets (%) binding 
fibrinogen and expressing P-Selectin (CD62P). Mean X = mean cell fluorescence in 
arbitrary fluorescence units. Fibrinogen binding was measured in resting platelets 
and following incubation with ADP, a weak agonist.
'Mann Whitney U test 
^Student’s Mest
3.5 Discussion
In this study platelets were analysed by whole blood flow cytometry to avoid the 
potential for in vitro activation, which can occur when preparing platelet rich plasma. 
Furthermore, it was possible to exclude activated samples by measuring the 
expression of baseline fibrinogen binding and P-Selectin. Since the resting level of
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binding in normal individuals is low, as illustrated in figure 3.2 and previously 
reported (Janes et al, 1993) samples were stimulated with ADP to expose the active 
fibrinogen binding sites on GPIIIa and amplify any possible allele dependent 
difference.
These data do not reveal a genetically determined difference in platelet fibrinogen 
binding patterns to plausibly support the lb  allele as a risk factor for thrombosis. 
Indeed, it was found that the density of fibrinogen binding sites in stimulated platelets 
was less in lb  platelets than those from subjects homozygous for HP A la. A greater 
increase in the percentage of platelets binding fibrinogen after ADP stimulation in lb 
subjects was not observed, in contrast to observations in patients with ischaemic heart 
disease studied by the same method (Goodall et al, 1999). This might reflect 
differences in studying platelet function in healthy subjects and in those with arterial 
disease. Given that the current study is o f comparable size to that o f Goodall et al, a 
similar allele dependent difference in fibrinogen binding should have been apparent, 
but a type 2  statistical error o f 2 0 % renders it possible that a smaller effect below the 
limit of detection may be present. However it is unclear whether such an effect 
would be of biological significance.
There was a tendency for more platelets from HP A lb  subjects to express P-Selectin 
than those homozygous for la, but this did not reach statistical significance. It is 
acknowledged that this study may be underpowered to detect a significant difference 
in P-Selectin expression, since the sample size was primarily determined to detect an 
effect on fibrinogen binding patterns. If  the observed differences are truly
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representative it is calculated that (given an approximate standard deviation of 0.25% 
calculated from the transformed data) 44 subjects with HP A lb  and 44 la /la  
homozygotes would be required for significance at the 5% level to be detected with 
80% statistical power.
Following completion of this study it could be suggested that any allele dependent 
differences may be small if  present at all, or may not be apparent in a relatively small 
study of healthy subjects. Such differences may be unmasked in disease states when 
platelet activity might be increased, and on recruitment of a larger sample size. Thus 
in order to plausibly demonstrate the lb  allele as a risk factor it is desirable to 
observe an effect in patients with acute arterial thrombosis. These points are 
addressed in chapter four, when the role of platelet activation markers and genotype 
was studied in patients following acute stroke.
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Figure 3.1. Scatterplot obtained on flow cytometry of whole blood. Platelets are 
identified by their size and granularity, and gated (small rectangle). SS=side scatter 
(granularity). FS=forward scatter (size).
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Figure 3.2. Histograms depicting platelet fibrinogen binding, before and after 
stimulation with ADP. Events with fluorescence falling within the horizontal bar are 
considered positive. This was adjusted for non-specific binding by moving the bar 
until a value of 0% was obtained with the FITC isotype control. FL=fluorescence.
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Figure 3.3. Histograms and scatterplots depicting platelet P-Selectin expression, as 
determined by dual binding with anti-GPIIIa and anti-CD62P. FL1=FITC. FL2=PE.
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Figure 3.4. Stimulation of P-Selectin expression in the same subject as figure 3.3 
following incubation with PMA.
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Figure 3.5. Percentage of platelets binding fibrinogen after 
stimulation with ADP. Mean values are denoted by horizontal bars.
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Figure 3. 6 Fibrinogen mean cell fluorescence following stimulation with 
ADP. Horizontal lines denote median values.
Chapter Four.
In vivo platelet activation in 
atherothrombotic stroke: relationship to 
polymorphisms of human platelet GPIIIa
and GPIb.
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4.1 Background
In chapter three a plausible effect o f the HPA lb allele on platelet function to 
support a role in thrombosis was not apparent in healthy subjects, and it was 
suggested that allele dependent effects might be revealed in patients with 
atherothrombotic stroke where platelet activity might be enhanced.
As discussed in chapter one, platelets have a pivotal role in thrombus formation 
following atheromatous plaque rupture (del Zoppo, 1998). Given the efficacy of 
antiplatelet therapy with aspirin in secondary prevention of acute arterial 
thrombosis (Antilatelet Trialists’ Collaboration, 1994), and that enhanced platelet 
aggregation has been shown prospectively to predict mortality following 
myocardial infarction (MI) (Trip et al, 1990), enhanced platelet activation might 
be a risk factor for arterial thrombosis. However, prospective data on platelet 
activitation as a risk factor for future stroke development are lacking. In case 
control studies platelet function has been measured either immediately following 
acute stroke (van Kooten et al, 1997; Zeller et al, 1999) or in the stable 
convalescent phase (Couch & Hassanein, 1976; Shah et al, 1985; van Kooten et 
al, 1999), but only one study has measured activation at both timepoints 
(Konstantopoulos et al, 1995), and reported persisting increased shear-induced 
platelet aggregation in fifteen patients with non-lacunar stroke.
As well as GPIIIa, platelet membrane glycoprotein GPIb (as part o f the Ib-V-IX 
complex) mediates platelet adhesion via vWF binding, and therefore is also 
important in mediating arterial thrombosis (Nurden, 1995). The HPA 2a/2b 
(KoVKo\ threonine at position 145 in 2a and methionine in 2b) and variable
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number of tandem repeats (VNTR) polymorphisms of the GPIb gene are in 
linkage disequilibrium, and have been studied as candidate risk factors for arterial 
thrombosis, since they might alter vWF binding. As was the case in studies of the 
HPA la /lb  polymorphism, some reports (Murata et al, 1997; Gonzalez-Conejero 
et al, 1998; Sonoda et al, 2000) but not others (Carter et al, 1998; Corral et al, 
2000) have linked the 2b allele of HPA 2a/2b and the C/B VNTR genotype with 
coronary artery and cerebrovascular disease. It has been suggested that the 
variability in the distance of the vWF binding site from the platelet surface seen 
with the VNTR polymorphism might influence platelet adhesion (Nurden, 1995), 
but there are currently no functional data to support these polymorphisms as 
thrombotic risk factors. The HPA 2a/2b and VNTR GPIb polymorphisms are not 
associated with density of surface receptor expression (Corral et al, 2000).
4.2 Aims
A case control study was performed to address these issues. There were three 
main objectives in this study:
i) Markers o f platelet activation were measured by flow cytometry immediately 
following atherothrombotic stroke and compared with healthy controls. 
Evidence o f persisting platelet activation was sought by resampling patients in 
the convalescent period (at least three months later).
ii) HPA la /lb  and 2a/2b allele frequencies were determined in patients and 
controls to investigate epidemiologically whether these polymorphisms are risk 
factors for stroke.
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iii) A correlation between polymorphisms and platelet function was sought by 
investigating the influence of genotype on the expression of platelet activation 
markers.
4.3 Methods
Patient and control selection, recruitment and sampling is described in chapter 
two.
4.3.1 Platelet flow  cytometry
Samples were treated in a standardised manner within one hour o f collection. 
Sample preparation and analysis was performed as described in chapter three. 
Platelets were analysed within 4 hours of preparation, although antibody binding 
was found to be stable for up to 6  hours if  stored at 4°C  (data not shown). The 
percentage o f platelets positive for P-Selectin and binding fibrinogen, and mean 
cell fluorescence as a measure of the average density of antibody binding per 
platelet, were recorded for each subject. Basal activation status was assessed in 
resting samples, and platelet reactivity following incubation with Adenosine 
Diphosphate (ADP) at a final concentration of 10 for 5 minutes (Sigma, St. 
Louis, USA).
4.3.2 DMA extraction
Leucocyte DNA was extracted using a proprietary kit. (Nucleon BACC 2 
Extraction Kit, Nucleon Biosciences, Coatbridge, UK). The following steps were 
taken:
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• Whole blood was centrifuged at 1300g for 15 minutes (MSE Chilspin 
centrifuge, Fisons, UK) and plasma removed.
• Buffy coats were transferred to a universal container, and approximately 5ml 
of Nucleon Reagent A (red cell lysis solution) were added.
• The mixture was shaken at room temperature for five minutes, and then 
centrifuged at 1300g for five minutes to precipitate white cells.
• The supernatant was carefully removed and 2ml Nucleon Reagent B (white cell 
lysis buffer) added. This was mixed until viscous, and left overnight at 37 ° C.
• The solution was transferred to a polypropylene tube and mixed with 500jil 
sodium perchlorate (supplied with kit).
• An equal volume (2.5ml) of 100% chloroform (BDH Laboratory Supplies, 
Poole, UK) was added.
• 250pl Nucleon resin were added and the mixture was centrifuged at 1300g for 
five minutes.
• The upper layer was transferred to a clean tube and two volumes o f cold 100% 
Ethanol (4ml) added to precipitate DNA.
• DNA was removed with a blue pipette tip, placed in an eppendorf tube, and 
washed with 70% Ethanol.
• The pellet was centrifuged at 5000g for five minutes (ALC Microcentrifuge, 
ALC International, Italy), allowed to dry then resuspended in lOmM 
Tris/EDTA.
The DNA concentration was assessed by spectrophotometry (PTP- 6  
Spectrophotometer, Perkin Elmer). 5pi were mixed with 245pi o f dHzO and the 
absorbance (A) at 260nm against a blank was recorded.. Since an A of 1.0 
corresponds to 50pg/ml of DNA, the final concentration was calculated by 
multiplying by 2500. The ratio of A280: A260 was recorded as an indicator of 
protein contamination. Samples with a high value underwent repurification by 
repeating the extraction steps above. Working dilutions of DNA at lOOng/pl were 
made by dilution with dHjO, which were stored at -70 °C until use.
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4.3.3 HPA la /lb  genotyping by PCR-SSP.
Principle
This method has been described previously (Cavanagh et al, 1997). Given that 
they differ from each other by a single nucleotide base at position 1565 in exon 2 
of the human GPIIIa (thymidine in la, cytosine in lb, Newman et al, 1989), 
alleles are distinguished by amplifying DNA by the polymerase chain reaction 
(PCR) using primers with this difference reflected at the 3’ end. In the absence of 
the allele no product is formed, since DNA polymerase incorporates nucleotides 
from the 3 ’ end of a strand. This technique is known as PCR with sequence- 
specific priming (PCR-SSP) or Amplification of Refractory Mutation System 
(ARMS).
Each patient sample is therefore subject to two PCR reactions, with la  and lb 
primers separately. A common primer is included to generate a 90 base pair (bp) 
product:
la  primer: 5TCACAGCGAGGTGAGGCCA3’ 
lb  primer: 5’TCACAGCGAGGTGAGGCCG3’
Common primer: 5’GGAGGTAGAGAGTCGCCATAG3’
The presence of an allele is therefore indicated by the presence o f a 90 bp product 
and its absence of by the absence of a product. Internal control primers for 
Human Growth Hormone (HGH) are added to the primer mix and generate a 429 
bp product, confirming success of the amplification reaction:
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5 ' GCCTTCCC AACC ATTCCCTT A3 ’
5 ’TCACGGATTTCTGTTGTGTTTC3 ’
Materials and methods
lOpl reactions were performed in thin walled tubes. Each contained:
• 200ng (2pl) patient or control DNA in dH,0.
• 1 pi NW3 PCR reaction Buffer.
• 0.35 units Taq polymerase.
• 0.2pl of deoxynucleotide triphosphates (dNTP).
• 0,1 pi o f Cresol Red lOmg/ml to assist visualisation o f product on 
electrophoresis.
• 5 pi of primer mix.
• dHzO to make a total volume of lOpl per reaction.
2pl of DNA were placed in a reaction tube containing 3pi of a master mix 
consisting o f nucleotides, buffer and Taq polymerase, plus 5pi of primers. 24 
samples were analysed in each experiment, a total of 48 PCR reactions per 
microtitre plate. Therefore the following mastermix (50 reactions) was used:
• lOpldNTP’s.
• 50pl NW3 buffer.
• 4pi Taq polymerase.
• 5 pi Cresol red.
• 81 pi dHgO.
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Using a PTC-200 Pelter Thermal Cycler (Genetic Research Instrumentation 
Limited, Dunmow, Essex, UK), the following temperature cycling conditions 
were applied ;
96°C initial dénaturation for 1 min; 5 cycles of 96°C for 25s then 6 8 °C for 45s 
then 72°C for 30s; 28 cycles of 96°C for 25s then 61°C for 45s then 72°C for 30s; 
72°C for 3 min. These had previously been determined to be the optimal cycling 
conditions using the above instrument at SNBTS Aberdeen, and differ from those 
described (Cavanagh et al, 1997).
lOpl of the product was electrophoresed on 1.5% Agarose gel at 200V for 
approximately 15 minutes in 0.5% Tris-Borate EDTA. The gel was stained with 
Ethidium Bromide, to enable visualisation by Ultra Violet fluorescence, and a 
photographic record obtained. A lOObp ladder was included in one lane of each 
gel to indicate the size of DNA bands.
In all experiments performed using this method the lb /lb  homozygote control 
cross-reacted with the la  primer mix, yielding a faint band following gel 
electrophoresis. Attempts were made to eradicate this mispriming (as suggested 
by Bottema & Sommer, 1993) by;
• Increasing the annealing temperature.
• Reducing Mg concentration.
• Reducing DNA concentration.
• Reducing primer concentration.
• Reducing dNTP concentration.
• Reducing Taq polymerase concentration.
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These manoeuvres were unsuccessful and resulted in either persistence of a band 
or failure of amplification altogether. Since HP A lb /lb  homozygotes were not 
unequivocally identifiable using this method, it was decided to abandon 
genotyping by SSP-PCR and use a restriction enzyme based method instead.
4.3.4 HP A la /lb  genotyping by PCR with restriction enzyme digest.
Principle
Substitution o f cytosine for thymidine at position 1565 in exon 2 o f the GPIIIa 
gene results in the sequence CCGG, a cleavage site for the restriction 
endonuclease msp 1. Using the following primers (Jin et al, 1993) amplification 
of genomic DNA by PCR yields a 266bp product:
sense: 5’TTCTGATTGCTGGACTTCTCTT3 ’ 
antisense: 5 ’TCTCTCCCCATGGCAAAGAGT3 ’
The a allele contains a single mspl site, yielding 221 and 45 bp fragments. The 
presence of a b allele is indicated by the presence of a second cleavage site, 
resulting in a 177 bp fragment. Alleles can therefore be separated 
electrophoretically (Weiss et al, 1996).
Optimisation o f PCR conditions 
Optimal PCR conditions were established by Mg titration. 4pl of 50ng/pl of 
genomic DNA were added to a 50pl thin walled PCR tube. To each tube the 
following were added:
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200ng genomic DNA.
2 0 pmol of each primer.
200pmol of dNTPs.
2 units Taq DNA polymerase. 
MgClz, varying between 0.5-5mM. 
20mM Tris HCl.
25mM KCl.
dHjO to a final volume of 50pl.
Each reaction was subject to the following conditions: 38 cycles of: dénaturation 
at 95 ° C for 60s; annealing at 60 ° C for 45s; and extension at 72 °C for 75s in a 
Techne Progene Thermal Cycler (Cambridge, UK.). 15 pi of product and 2 pi of 
loading dye were pipetted onto a 2% agarose gel, electrophoresed at 75V for two 
hours, and stained with ethidium bromide. The product band stained weakly over 
the range of Mg concentrations, indicating an inefficient PCR reaction. It was felt 
that the digested product would be difficult to visualise following further dilution 
in enzyme reaction buffer, and the thermal cycling conditions were altered by 
increasing the duration of each temperature cycle as indicated below:
• Dénaturation at 94 ° C for two minutes, 1 cycle;
• Dénaturation at 94°C  for one minute, annealing at 60°C for two minutes, 
extension at 72 ° C for 2.5 minutes, 35 cycles;
• Extension at 72 ° C for ten minutes, one cycle.
This produced a satisfactory product, and it was then determined that optimal 
MgClz concentration was 2mM per reaction. In subsequent reactions 4pi of
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genomic DNA was added to 16pl of a mastermix solution and 30pl of dHgO. The 
mastermix contained (per reaction):
5 pi of lOX Reaction Buffer.
Ip l of dNTP’s.
2 pl sense primer (lOpmol/pl).
2  pi antisense primer (lOpmol/pl).
4pl 25mM MgClj.
0.4pl Taq polymerase.
1 .6 pl dHzO.
The thermal cycler processed 20 samples in a single run, consisting of a blank, 16 
subject samples and three controls of known genotype.
Restriction enzyme digest 
Conditions were optimised using subjects o f known genotype (kindly supplied by 
Dr G Cavanagh, Newcastle Blood Transfusion Service). The PCR product was 
incubated overnight at 37°C with 20 units of mspl. 15pi of product were added 
to 15pl of a mastermix consisting of (per reaction):
• 3 pi Buffer Y.
• 2pl mspl (lOunits/pl).
• lOpldHjO.
13 pi of the product plus 2pl of loading dye were electrophoresed on 4% (4g in 
100 ml of TBE) agarose gel for two hours at 90 volts. An example of the bands 
obtained to discriminate individual genotypes is given in figure 4.1.
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Quality assurance
Each experiment included a blank (no DNA) to exclude reagent DNA 
contamination. Samples o f known genotype were included in every experiment. 
Analyses were repeated at random to confirm the reproducibility of the method; 
three samples (one HP A la /la  and two la /lb ) were genotyped three times each 
and the same result was obtained every time. Occasionally difficulty 
discriminating homozygous lb /lb  from heterozygous la /lb  samples was 
encountered, as evidenced by the presence of both 177 and 221 bp bands in the 
enzyme digest o f the HP A lb /lb  control. When this occurred the experiment was 
repeated. This occurred on three occasions and coincided with use o f the last 
aliquot o f a batch of enzyme. This difficulty was overcome by increasing the 
concentration of enzyme used to 30 units per reaction.
4.3.5 HP A 2a/2b genotyping by PCR-SSP
This was determined using the reaction conditions described in 4.3.3 using the 
following primers to obtain a 258bp product:
2a primer: 5’GCCCCCAGGGCTCCTGAC3’
2b primer: 5 ’GCCCCCAGGGCTCCTGAT3 ’ 
common primer: 5 'TCAGCATTGTCCTGCAGCCA3 ’
Unlike the HP A la /lb  genotyping no mispriming was encountered with this 
method. These experiments were performed by Miss Irene Moore in SNBTS
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Aberdeen, in a laboratory which is accredited by the Clinical Pathology 
Association of the UK (CPA) and which performs satisfactorily in a national 
external quality assurance scheme (NEQAS, Sheffield, UK).
4.3.6 Plasma fibrinogen concentration
Assays were performed in the Haematology laboratory at Aberdeen Royal 
Infirmary. 4.5ml of whole blood anticoagulated in 3.9% trisodium citrate were 
collected in a Vacutainer® sample tube (Becton Dickinson, Cedex, France), and
analysed in an ACL 3000 coagulometer (Instrumentation Laboratory, Warrington, 
UK). This is a fully automated technique, and plasma fibrinogen concentration 
was derived from a prothrombin time. The sample was placed on an autoanalyser 
after centrifugation at lOOOg for ten minutes to separate plasma from cells. 
Plasma was mixed in the analyser automatically with the PT reagent, consisting of 
calcium and rabbit thromboplastin (IL TEST™ PT-Fibrinogen, Instrumentation 
Laboratory, Warrington, UK) to induce clot formation. This was detected 
nephelometrically, as the analyser detects the change in light scatter produced by 
thrombus formation. Following coagulometer calibration with standards of 
known concentration (IL Calibration Plasma, IL, Warrington, UK), a plasma 
fibrinogen concentration was calculated.
Quality Assurance
The laboratory performing this assay is CPA accredited. Internal quality control 
is assessed by the analysis o f control samples o f known fibrinogen concentration 
(Lyophilised normal and abnormal pooled plasma, Baxter Immuno, Wien
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Germany). The intra- and interassay coefficients of variation are consistently 
<5%. The laboratory also participates in NEQAS, and performance to date has 
been satisfactory.
4.3.7 Platelet count and mean platelet volume (MPV)
These were performed in the Haematology laboratory at Aberdeen Royal 
Infirmary, using a Bayer Technicon H3 autoanalyser (Bayer, Cedex, France). 4.5 
ml of tripotassium EDTA anticoagulated whole blood were collected in a 
Vacutainer® sample tube (Becton Dickinson, Cedex, France) for full blood count
(FBC) analysis. Cells are identified by flow cytometry, and platelet number and 
size are assessed by forward (size) and side (granularity) light scatter 
characteristics.
The laboratory is CPA accredited, and also participates in the NEQAS scheme for 
FBC analysis. Three control samples (Bayer, Cedex, France) are analysed daily 
to assess interassay precision, and consist of:
i) Testpoint™ Control normal; Platelets 225±30 xlOVl, MPV 8 .7± l.lfl.
ii) Testpoint™ Control low; Platelets 80± 15x1071, MPV 8.2±1.2fl.
iii) Testpoint™ Control high; Platelets 480+60 xlOVl, MPV 8 .3± l.lfl.
Results are accepted if the control sample results fall within these ranges.
In addition a sample received in the laboratory with values within the normal 
range is analysed thrice daily. A log of all quality assurance procedures is kept 
and signed daily to ensure adherence.
70
4.3.8 Fasting total cholesterol, and LDL, HDL and triglyceride 
quantitations.
These assays were performed in the Biochemistry laboratory at Aberdeen Royal 
Infirmary using a DAX-72 autoanalyser (Bayer, Basingstoke, UK). This is a CPA 
accredited laboratory which participates satisfactorily in a NEQAS scheme.
4.3.9 Statistical analysis
Calculations were performed using SPSS for Windows version 8.0 statistical 
software. The distributions o f genotypes, allele frequencies and clinical risk 
factors for arterial disease in cases and controls were compared by Chi-square 
tests. Odds ratios (OR) and 95% confidence intervals (Cl) were calculated using 
standard formulae.
Platelet activation data were visualised in boxplots (figures 4.2-4.4). Boxes 
display the median and the 25th and 75th centiles, and whiskers represent 
extremes of the data. Outliers are arbritrarily defined as lying >1.5 boxlengths 
from the median, and are not plotted. Skewed continuous variables were 
normalised by log,o transformation, and geometric means calculated. In order to 
avoid the influence o f artefactual platelet activation, values greater than three 
standard deviations fi*om the mean were excluded. Numbers quoted in individual 
groups are therefore less than the total number analysed. Results were not altered 
by the inclusion o f these outliers in analysis (data not shown). Mean differences 
between patients and controls were analysed by Student’s ^-test, and between 
acute and convalescent patient variables by paired /-tests of transformed data.
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Unpaired skewed continuous variable medians were compared with the Mann- 
Whitney U test. A two-tailed p value of <0.05 was considered significant. The 
effect o f genotype on expression of activation markers was assessed by analysis of 
variance (ANOVA) of transformed data and by Scheffe’s post hoc analysis for 
multiple comparisons.
4.4 Results
The outcome of study recruitment is described in chapter 2.
4.4.1 Platelet genotpe distributions
The distributions of platelet genotypes and allele frequencies are summarised in 
table 4.1. The lb  allele was not overrepresented in patients, and there was no 
difference in distribution of the HP A la /lb  or HP A lb /lb  genotypes between 
cases and controls. There was no significant difference in lb  allele distribution 
{allele frequency} when analysis was restricted to subjects under the age o f 60 
(16/79 {0.20} vs 22/90 {0.24}, OR (Cl) 0.8(0.4-1.6). There was no 
overrepresentation of the HPA 2b allele in the entire study cohort, nor in those 
under 60 (n=80, 16/160 {0.10} vs 16/184 {0.09}, OR 1.01(0.5-2.1). The number 
of patients heterozygous or homozygous for the HPA 2b allele did not differ 
statistically significantly from controls, and there were no differences when those 
under 60 were studied.
4.4.2 Platelet activation 
Data on platelet expression of P-Selectin and fibrinogen binding are summarised 
in table 4.2. There were significantly more platelets expressing P-Selectin in
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acute stroke than in control samples (p<0.001, Student’s /-test), and this 
difference persisted into the convalescent period (p<0.001, Student’s /-test). This 
is illustrated in figure 4.2. The proportion of platelets binding fibrinogen was also 
greater in acute and convalescent stroke patients compared to controls (p<0 . 0 0 1  
and p=0.002 respectively, Student’s /-test). We found no statistical difference in 
mean percentage P-Selectin expression between the acute and convalescent 
periods in patients who provided a sample at both times (p=0.67, paired /-test), 
but the number of platelets binding fibrinogen decreased from a geometric mean 
of 2.1% in the acute period to 1.4% in the convalescent period (p=0.02, paired /- 
figure 4.3). Values obtained immediately after stroke correlated with follow 
up values (f=0.431, p<0.001 for log;o%CD62P expression and f=0.231, p=0.048 
for logjofibrinogen binding). There was also evidence of a persisting greater 
density of anti GPIIIa binding sites in stroke patients, as evidenced by greater 
mean cell fluorescence in acute and convalescent patients compared to controls 
(p<0.001 and p=0.008 respectively, Student’s figure 4.4). There was no
alteration in mean cell fluorescence between the acute and convalescent periods 
(p=0.26, paired /-test). No difference in mean cell fluorescence for P-Selectin 
expression or fibrinogen binding between acute, convalescent and control samples 
was detected (data not shown). There were no differences in results when 
analyses were restricted to the 1 1 2  patients for whom a matched control was 
available (data not shown). Neither CD62P expression (f=-0.09, p=0.12) nor 
fibrinogen binding (f=-0.08, p=0.58) correlated with plasma fibrinogen 
concentration.
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Evidence of reduced platelet reactivity immediately after stroke was detected 
{table 4.2), since the percentage of platelets binding fibrinogen following 
stimulation with ADP was lower in the acute phase than in controls (p<0.001). 
The density of fibrinogen binding sites after ADP stimulation did not significantly 
differ between the three groups (acute geometric mean {range} mean cell 
fluorescence 8.45 {2.0-39.8} units vs 7.66{2.3-37.2} in controls, p=0.15, Student’s 
/-test; convalescent mean 7.69 (2.1-46.8) p=0.1 vs controls, p>0.95 vs acute, 
paired /-test).
Of 146 patients with evaluable data 48 (33%) were taking aspirin at the time of 
their stroke. Those not taking aspirin had significantly greater numbers of 
platelets binding fibrinogen than those who did not (median{range} 1.5%{0.2- 
5.5} vs 1.2{0.2-4.4}, p=0.05, Mann-Whitney U test). There was also a tendency 
for those not on aspirin to have more platelets expressing CD62P, but this was not 
statistically significant (0.70%{0.1-1.85} vs 0.53{0.1-1.81}, p=0.1, Mann- 
Whitney U test). In a subset of the study cohort (n=35) the effect of commencing 
aspirin following stroke on platelet activation was assessed. No significant 
difference in the expression of CD62P (median{range} 0.7%{0.1-1.85} before 
aspirin cf 0.5% {0.1-1.81} after, p=0.2, Wilcoxon ranked signs test) nor in 
fibrinogen binding (1.4%{0.4-5.3} before aspirin vs 1.2%{0.2-4.3} after, p>0.95, 
Wilcoxon ranked signs test) was found.
4.4.3 Platelet genotype and activation 
There was no statistically significant difference in the median number of platelets 
expressing P-Selectin in patients and controls homozygous or heterozygous for
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HPA lb (n=57) compared with those (n=201) with the la /la  genotype (geometric 
mean {range} 0.49{0.1-4.37}% vs 0.51 {0.1-6.46}% respectively, p=0.83. 
Student’s /-test). There was no HPA la /lb  genotype dependent difference in 
platelet fibrinogen binding (geometric mean 0.86{0.1-13.5}% in those with the lb 
allele vs 0.9{0.1-18.2}% in individuals with the la /la  genotype, p=0.78. 
Student’s /-test). No genotype dependent difference in antiGPIIIa binding density 
was observed ( la  mean{SD} 9.1 {2.1} fluorescence units vs lb  9.0{1.7}, p=0.88. 
Student’s /-test). No difference in platelet reactivity based on genotype as 
assessed by fibrinogen binding patterns following stimulation with ADP was 
identified ( la  mean {SD} 59.1 {17.5}% vs lb  56.6{16.9}%, p=0.53, Student’s /- 
test).
Platelet activation was not dependent on HPA 2 genotype, since those possessing 
the 2b allele (n=43) did not have greater numbers of platelets binding fibrinogen 
or expressing P-Selectin than those homozygous for HPA 2a (n=214): Platelet 
fibrinogen binding 2a geometric mean {range} 0.9{0.1-18.2}% vs 2b 0.9{0.1- 
13.5}%, p=0.78, Student’s /-test; P-Selectin 2a geometric mean {range} 0.9{0.1- 
18.2}% vs 2b 0.9 {0.1-10}%, p=0.90). Mean cell fluorescence for antiGPIIIa 
binding was not dependent on genotype (2a mean{SD} 8.0{3.5} vs 2b 7.8{3.5}, 
p=0.65. Student’s /-test). No difference in platelet reactivity was identified (2a 
mean{SD}fibrinogen binding after ADP 61.1 {18.1}% vs 2b 64.6{14.8}, p=0.18. 
Student’s /-test).
The effect o f the lb  and 2b alleles in the acute phase, the convalescent phase and 
in controls were investigated separately by ANOVA and Scheffe’s test for
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multiple comparisons. Results are summarised in table 4.3. No subgroup of lb  or 
2b subjects exhibited greater fibrinogen binding or P-Selectin expression than 
their la /la  or 2a/2a counterparts. Subgroup analysis did not identify differences 
in fibrinogen binding following stimulation with ADP.
It was determined whether allele dependent altered sensitivity to aspirin was a 
potential confounding factor in the study. Results are summarised in table 4.4. 
There was no difference between la  and lb  platelets nor 2a and 2b containing 
platelets in expression o f activation markers in those who were taking aspirin at 
the time of sampling and those who were not.
4.5 Discussion
Difficulties in interpreting conflicting data from epidemiological studies of 
platelet polymorphisms has given rise to the view that genetic influences are 
modified by environmental factors, so that only certain patients may be at 
increased risk (eg smokers, those of young age or female gender), and subgroup 
analysis may be necessary to identify these risk groups (Carter et al, 1998; 
Wagner et al, 1998; Bray, 1999). However, epidemiological studies of modest 
size which conduct subgroup analyses are likely to overestimate the risk, 
especially given the publication bias associated with positive studies (Ridker & 
Stampfer, 1999a). Thus it has been suggested only large population based studies 
should be undertaken to study the association of genetic polymorphisms with 
arterial disease (Ridker & Stampfer, 1999a; Keavney et al, 2000). In this 
modestly sized study epidemiological data was combined with an investigation of
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the influence of polymorphisms on platelet function. Evidence of platelet 
activation in the acute and convalescent phases o f stroke was found, but there was 
no association between the HPA la /lb  and 2a/2b polymorphisms o f GPIIIa and 
G Plb respectively and expression of these markers in neither healthy controls nor 
patients in the acute and convalescent periods of stroke. There was no significant 
epidemiological association with genotype and atherothrombotic stroke in the 
study cohort, even when analysis was restricted to younger patients (less than 60 
years).
It has been suggested that HPA lb, as a polymorphism of the platelet fibrinogen 
receptor might mediate increased risk of thrombosis by enhancing platelet 
fibrinogen binding (Bray, 1999). In chapter three no such relationship was 
demonstrated in platelets from healthy subjects, and these findings are replicated 
in this study, despite evidence o f increased numbers o f platelets binding 
fibrinogen following stroke. It is acknowledged that platelet genotype may 
influence function by another mechanism, and it has been suggested the HPA 
2a/2b polymorphism may result in altered vWF binding in the conditions o f high 
shear stress seen in arteries narrowed by atheroma (Bray, 1999), but data to 
support this are lacking. However, both P-Selectin expression and fibrinogen 
binding occur in the later stages of platelet activation (del Zoppo, 1998), and 
although GPIIIa and GPIb polymorphisms may not influence these directly, any 
effect on platelet activity should ultimately be reflected in these endpoints. The 
only study conducted prior to this one to demonstrate enhanced lb  platelet activity 
compared to la  recruited a much larger cohort than other functional studies (Feng 
et al, 1999), and did not study in vivo activation during an acute thrombotic event.
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It is recognised this study may be underpowered to detect a more modest effect, 
but it is unclear whether a smaller in vitro effect would be sufficient to influence a 
clinical event like thrombotic stroke.
The study of stroke pathophysiology is associated with particular difficulties. 
Stroke arises from numerous processes, including intracranial haemorrhage, 
cardiac embolisation, atherothrombosis (rupture of either large vessel atheroma 
with cerebral embolism or o f small vessel atheroma with thrombotic occlusion), 
and vasculitis. Most studies have failed to distinguish between these diverse 
stroke types (Couch & Hassanein, 1976; Dougherty et al, 1977; Hoogendijk et al, 
1979; Shah et al, 1985; van Kooten et al, 1997; van Kooten et al, 1999) and any 
individual risk factor might influence only one of these processes. Subjects with a 
single underlying pathophysiological process were therefore studied. An 
association of atherothrombotic stroke with smoking, hypertension and plasma 
fibrinogen concentration was confirmed, but there was no association with 
diabetes mellitus, hyperlipidaemia nor family history of arterial events. This lack 
of association between family history of thrombosis and stroke, and the 
observation of no association between platelet genotype and stroke in our cohort 
further support the view that the influence of a single gene on cardiovascular 
disease is weak (Ridker & Stampfer, 1999a).
In vitro measurements of platelet function may not necessarily reflect in vivo 
activity. In particular, assays of plasma beta thromboglobulin, platelet factor 4 
(Shah et al, 1985) and platelet aggregometry (Couch & Hassanein, 1976; 
Dougherty et al, 1977; Konstantopoulos et al, 1995) are susceptible to artefactual
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platelet stimulation as a result o f centrifugation and stirring procedures 
(Michelson, 1996). Platelet function was studied directly by whole blood flow 
cytometry to avoid this effect, and was related to polymorphisms of receptors that 
have a major role in platelet recruitment in acute thrombus formation (Nurden, 
1995). Artefact was further minimised by careful blood sampling and by 
excluding values greater than three standard deviations from the mean from 
statistical analysis. However, it should be acknowledged that this study assessed 
function in circulating platelets. This may not necessarily reflect localised platelet 
activity within the thrombus in the acute phase of stroke, and as such remains an 
indirect assessment o f in vivo platelet function in arterial thrombosis. This point 
is illustrated by the observation that the absolute numbers of platelets expressing 
activation markers is a fraction o f the total platelet count in patients {table 4.2).
Prospective data on platelet activity as a risk factor for future stroke development 
are lacking, but this study found evidence of persisting platelet activation in 
stroke, indicated by circulating platelets expressing P-Selectin and binding 
fibrinogen, and by greater density of GPIIIa binding in both the acute and 
convalescent phases. Although platelet activity immediately after stroke may 
reflect a secondary response to tissue injury (Robertson et al, 1980; Dougherty et 
al, 1979), the observation of persisting platelet activation may indicate an 
underlying prothrombotic tendency. Reduced platelet responsiveness in acute 
stroke was observed, indicated by reduced numbers of platelets binding fibrinogen 
following stimulation with ADP. This is consistent with circulation o f activated 
platelets which are no longer susceptible to further stimulation. These changes
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are clearly subtle, since they are not reflected in altered numbers o f circulating 
platelets nor in their mean volume.
Although an association between raised mean platelet volume and increased 
mortality following MI has been suggested (Martin et al, 1991), there was no 
association between MPV and stroke in this study. It is acknowledged that the 
timing o f full blood count analysis was not identical for every sample, and despite 
the fact that all were analysed within two hours of collection, in vitro increases in 
MPV in EDTA are measurable within this period (Trowbridge et al, 1985).
Potential confounding by aspirin use was investigated, as it has been suggested 
that sensitivity to aspirin may be influenced by platelet HPA la /lb  genotype 
(Cooke et al, 1998). There was no difference in expression of activation markers 
between la  and lb  platelets nor 2a and 2b platelets in either subjects who were 
taking aspirin and those who were not. The observation of greater platelet 
activation in those subjects not taking aspirin on admission, and the subsequent 
failure to reduce this when aspirin was commenced after stroke, suggests that a 
subgroup of patients might benefit from additional antiplatelet therapy. This was 
performed in a subgroup of the study cohort, and it is possible that a small effect 
was not detected as a result o f type 2 statistical error. A larger study is therefore 
required to investigate this specifically.
In conclusion there is evidence of platelet activation in acute atherothrombotic 
stroke, which persists months after the acute event. This suggests that platelet 
activation is a marker of a prothrombotic state, and may be involved in the
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pathogenesis of acute stroke. However, neither the HPA lb  nor HPA 2b allele is 
associated with stroke, and they do not appear to influence in vivo platelet 
activation. These data do not support these polymorphisms of platelet membrane 
GPIb and GPIIIa as risk factors for atherothrombotic stroke in the Grampian 
population.
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PCR with MSP 1 digest
300 bp 
200 bp
ladder lb/lb la/la
Uncut la/lb
Figure 4.1. HPA la/lb  genotypes following msp I  
digest.
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Genotype Patients (n=150) Controls (n=150) Significance
la /la 118 112 X^=0.67, p=0.41
la /lb 31 36 1 df
lb /lb 1 2
2a/2a 122 128 A^O.86, p=0.35
2a/2b 27 22 1 df
2b/2b 1 0
Allele Frequency Odds Ratio (Cl)
la 267/300 (0.89) 260/300 (0.87) 0.8(0.5-1.3)
lb 33/300 (0.11) 40/300 (0.13)
2a
2b
271/300 (0.91) 
29/300 (0.09)
278/300 (0.93) 
22/300 (0.07)
1.4 (0.8-2.4)
Table 4.1. Genotype distributions and allele frequencies. 
Heterozygous and homozygous carriers of HPA lb or 2b were 
combined for chi square analysis. df=degrees of freedom. CI=95% 
confidence intervals.
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Chapter Five
Plasma Homocysteine concentrations in 
the acute and convalescent phases of
atherothrombotic stroke.
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5.1 Background
Homocysteine is a thiol containing amino acid which is derived solely from the 
metabolism of dietary methionine. It circulates in plasma in three forms: as a single 
free amino acid homocystine (1%); as homocysteine or cysteine-homocysteine 
disulphides (20-30%); or bound to plasma proteins (70-80%). Together these account 
for total plasma homocysteine (tHcy). There are two main routes o f metabolism 
(summarized in figure  5.7): remethylation to methionine using either folate or (in the 
liver) betaine as a methyl donor, or transulphuration ultimately to cysteine. These 
reactions are dependent on cofactors, including vitamin B12 and folate for 
remethylation, and vitamin B6 for transulphuration. When plasma methionine is 
raised (for example following a protein rich meal) transulphuration is the main route 
of metabolism, while in fasting conditions remethylation predominates.
Homocystinuria is a rare inborn error of metabolism (approximately 1 in 100 000 live 
births) arising from homozygous deficiency of Hey metabolizing enzymes, usually 
cystathionine B synthase, which results in extremely high tHcy concentrations 
(>100pmol/l, severe hyperhomocysteinaemia). This is associated with mental 
handicap; skeletal and ocular lens abnormalities; and premature arterial and venous 
thrombosis in 50% of untreated patients by the age of thirty years, possibly as a result 
of oxidative damage mediated by the sulphydryl group o f free single chain 
homocystine (Mudd et aZ, 1985).
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It is less clear whether smaller elevations of tHcy are associated with thrombosis. 
Heterozygotes for cystathionine B synthetase deficiency have normal or raised tHcy 
concentrations, but studies of an association with thrombosis are conflicting (Boers et 
al, 1985; de Valk et al, 1996). Mild hyperhomocysteinaemia (HHC, concentration 
>95* centile of the normal range, which is approximately 5-15pmol/l) results from 
nutritional and more subtle genetic influences. Subclinical deficiencies of folate, 
vitamins B12 and vitamin B6 (Selhub et al, 1993) are associated with these mild 
elevations. Other conditions including renal impairment, hypothyroidism and drug 
therapy (e.g. folate antimetabolites, theophylline, smoking or oral contraceptives) are 
also associated with mild hyperhomocysteinaemia (Hankey & Eikelboom, 1999). 
Whether this can cause premature arterial thrombosis is a contentious issue. 
Retrospective case control studies have associated HHC with both arterial and venous 
thrombosis (Graham et al, 1997; den Heijer et al, 1996). In contrast, results from 
prospective studies have been inconsistent, both supporting (Stampfer et al, 1992; 
Wald et al, 1998; Arnesen et al, 1995; Nygard et al, 1995) and refuting (Chasan- 
Taber et al, 1996; Evans et al, 1997; Folsom et al, 1998) hyperhomocysteinaemia as 
a risk factor for myocardial infarction (MI).
Consideration o f reports of plasma tHcy and stroke identifies similar difficulties. 
Case control studies reported stronger associations (Graham et al, 1997; Yoo et al,
1998) than prospective studies, where some (Perry et al, 1995; Giles et al, 1998) but 
not others (Alfthan et al, 1994; Verhoef et al, 1994) claimed that raised plasma 
homocysteine concentration is a risk factor for future stroke development.
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A genetic influence on Hey concentration has been investigated. The thermolabile 
variant of methylenetetrahydrofolate reductase (MTHFR) arising due to homozygous 
substitution of cytosine by thymine at position 677 is common, found in 
approximately 12% of Western populations (Brattstrom et al, 1998), and is associated 
with defective remethylation due to reduced enzyme activity (Frosst et al, 1995). 
Subjects with this genotype have raised fasting tHcy concentrations, especially when 
folate is low (Malinow et al, 1997), Despite this most studies have failed to identify 
the TT genotype as an independent risk factor for arterial thrombosis (Brattstrom et 
al, 1998). This lack of association between genotype and a clinical endpoint has 
raised further doubt about the role of homocysteine in vascular disease.
Two further issues are relevant:
1) As discussed in chapter one stroke arises from numerous pathophysiological 
processes including haemorrhage, cardiac embolisation, atherothrombosis and 
vasculitis. Most studies have failed to distinguish between these diverse stroke types, 
and any individual risk factor might influence only one of these processes. Recent 
studies in humans have shown that acute hyperhomocysteinaemia after methionine 
loading causes endothelial dysfunction, which might promote atheroma development 
(Chambers et al, 1999; Nappo et al, 1999). Furthermore raised homocysteine 
concentrations are associated with asymptomatic carotid artery wall thickening and 
stenosis (Malinow et al, 1993; Selhub et al, 1995), and correlate with the severity of
93
cerebral artery stenosis (Yoo et al, 1998). It could therefore be postulated that 
elevated tHcy is a risk factor for atherothrombotic stroke in particular.
2) Very few data are available regarding tHcy concentration immediately after acute 
stroke. There is currently debate about whether tHcy is a causative risk factor in 
stroke and MI, or is merely a secondary marker o f risk in survivors (Kuller & Evans, 
1998; Dudman, 1999). Such data would help to resolve this question, since the 
observation of a raised tHcy immediately following acute stroke would be more 
suggestive of a causal association than the occurrence of hyperhomocysteinaemia in 
survivors sampled at a time distant from the event.
5.2 Aims
A case control study was designed to address these issues. This was restricted to 
subjects with atherothrombotic stroke by exclusion of cases of intracranial 
haemorrhage and likely cardioembolic or vasculitic aetiology as described in chapter 
two. Subjects were recmited between June 1997 and December 1998. Fasting tHcy 
concentrations were measured in both the acute and convalescent periods of stroke, 
and any change in tHcy between these times assessed. Changes in factors known to 
affect Hey metabolism, such as B12 and folate concentrations, smoking habit and 
drug history, were also assessed to determine whether these were responsible for any 
observed change in tHcy concentration observed between the acute and convalescent 
period.
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5.3 Methods
Patient and control recruitment and sampling is described in chapter two.
5.3.1 Total plasma homocysteine assay by reverse phase HPLC and 
fluorescent detection.
Principle o f HPLC
High performance liquid chromatography (HPLC) utilizes the principle that the 
passage of a substance in solution over a column is delayed if it interacts with that 
column. In this way conditions can be manipulated to separate a given substance 
from a mixture, since it will be released from the column by elution at a specific time 
compared to other substances. (In this case thiol amino acids can be separated from 
each other and other constituents of plasma). The conditions of the column are 
manipulated to enhance the separation. There are two main constituents in HPLC:
1) The mobile phase is the solvent used to transport the sample.
2) The solid phase is the column which the sample interacts with. The main 
constituent is usually silica gel.
These constituents are manipulated to enhance the separation of the molecule under 
study, and are therefore dependent on the chemical and physical properties of the 
substance assayed. There are therefore four types of HPLC (Bird, 1989):
i) Normal phase chromatography is used to separate hydrophilic molecules by 
enhancement of hydrophilic binding on the column.
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ii) Reverse phase chromatography: hydrophobic molecules are adsorbed onto the 
silica column.
ill) Ion exchange chromatography: positively or negatively charged molecules are 
attracted to their opposite in the silica molecules of the column, 
iv) Size exclusion chromatography; pores in the silica hamper the passage of larger 
molecules.
Reverse phase HPLC is used in Hey analysis since it is an organic hydrophobic 
molecule. The optimal solid and mobile phase conditions for its separation from 
other thiol containing amino acids have been determined (Ubbink et al, 1991).
Sample preparation
Samples were analysed between February and May 1999. They were thawed and 
80 pi o f plasma and 20 pi dHjO mixed in an eppendorf. The following steps were then 
performed in a standardised manner:
• Reduction.* Protein-bound homocystine and disulphide form s are converted to 
single thiols by mixing with a reducing agent. Samples were reduced by the 
addition of lOpl of 10% tri-n-butylphosphine (Sigma Chemicals, St Louis, USA) 
in a fume hood. These were mixed thoroughly and placed at 4°C  for 30 minutes 
to ensure complete reduction. Protein was precipitated by the addition of 1 lOpl of
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10% Trichloroacetic acid (BDH Laboratory Supplies). This was mixed 
thoroughly, stored at 4 °C for 10 minutes and centrifuged at 14,000 rpm for 10 
minutes.
• D erivatisation.* Homocysteine is conjugated with a derivatising agent. This is a 
compound with no inherent fluorescent properties in the free  state, which when 
bound will fluoresce on laser excitation, enabling detection. lOOpl of clear 
supernatant were then added to a second eppendorf containing the derivatisation 
compound: lOOpl SBD-F (ammonium-7 fluoro-2,1,3-benzoxadiazole sulphonate, 
Fluka, New-Ulm, Switzerland) 0.5mg/ml in borate buffer; 50pl 3M NaOH (BDH 
Laboratory Supplies, Poole, UK); and 200pl O.IM borate buffer. Samples were 
incubated for one hour at 60 ° C on a heating block to allow full derivatisation, and 
the reaction then stopped by placing on ice for 5 minutes. 18.5pl of 
orthophosphoric acid were added to adjust pH to 2.2.
• Reverse phase HPLC and data  processing.*. Reduced and derivatised 
homocysteine is passed over the column in mobile phase, and detected by 
spectrophotometry, and a real time record o f  detected fluorescence is produced. 
Samples were transferred to autoanalyser tubes (Gilson Medical Electronics, 
Villiers-Le-Bel, France). These were mounted on a Gilson 715 HPLC and 
fluorometer apparatus (Gilson Medical Electronics, Villiers-Le-Bel, France). The 
following components were utilised to optimise separation of thiol amino acids;
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1) Mobile phase consisted of 7% actetonitrile (ACN) in 25mM Potassium dihydrogen 
phosphate buffer, pH 2.2.
2) Solid phase. A 100x4.6mm Hichrom RBP (Hichrom, Reading UK) containing 
spherical 5pm silica particles.
The circuit also contained a precolumn (Hichrom, Reading, UK) to minimise 
degradation of the column in acidic conditions.
115pl were aspirated by the autosampler and injected into the mobile phase, which 
was passed over the column at a rate of 0.6ml/min, at a pressure of 70 bar generated 
by two pumps. After passing through the column the separated sample components 
were detected by fluorometry. Excitation with a 385nm light-source results in a 
515nm signal from SBD-F derivatised thiols. This was processed with a 
microcomputer utilising 715 HPLC System Controller software (Gilson Medical 
Electronics, Villiers-Le-Bel, France), and a real-time chromatogram trace of 
fluorescence against time produced. Peaks corresponding to homocystine, cysteine 
and cysteinglycine were obtained (figure 5.2.). The time a peak appears is known as 
the retention time (RT) and is dependent on the degree of interaction with the solid 
phase. This was usually between four and five minutes for homocysteine in the 
laboratory.
• Calculation of total plasma homocysteine. The mean area under the curve for 
each sample was obtained from the duplicate values, and this was compared with 
the value obtained from a standard concentration of lOpM to calculate the plasma
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Hey concentration. The area corresponding to a plasma concentration of lOpmol/l 
was calculated from the value obtained from a pooled normal plasma sample to 
which lOpM of L-Hcy were added (‘spike sample’) and subtracting the value 
obtained from the pooled normal plasma alone (‘blank sample’). The value for 
each sample was therefore calculated thus:
area from sample x 10 
‘spike’ minus ‘blank’
Quality control considerations 
Each assay batch contained a combination o f acute, convalescent and control 
samples, and the operator was blinded to the identity o f individual samples. 
Reproducibility of the assay was assessed by calculating intra- and inter- assay 
coefficients of variation (CV). The intra-assay CV was calculated by analysing a 
single sample in all tubes on a run, and yielded a value o f 4.2%. The inter -assay CV 
was calculated from the value derived from the same plasma sample which was 
analysed in different runs. A value o f 18.9% was obtained after the first tens runs by 
single sample analysis. This was reduced to 11.7% by using duplicates in subsequent 
runs, and samples initially analysed singly were therefore reassayed in duplicate. 
Samples with extreme values (<4pmol/l or >20pmol/l) were reanalysed to confirm 
reproducibility of those results. In each run the retention time was recorded and a 
value between four and five minutes considered acceptable. Prolongation of the RT 
indicated impaired homocystine elution and that batch was reanalysed.
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5.3,2 Serum B12 and red cell folate assays.
These assays samples were prepared in the routine Haematology laboratory at 
Aberdeen Royal Infirmary, and analysed on a Technicon Immuno 1® autoanalyser 
(Bayer Technicon, Cedex, France). Both B12 and RCF concentrations were 
elucidated by a competitive magnetic separation assay (MSA). The principle of B12 
estimation is summarised below:
1) Release o f B12 from protein binding by incubation with pretreatment reagent.
2) Released B 12 is mixed with Intrinsic Factor reagent (IF), which binds to it.
3) A B12-Alkaline Phosphatase (ALP) enzyme conjugate is added to the sample, 
which competes with endogenous B 12 for IF binding sites.
4) Monoclonal immunomagnetic particle reagent (mlMP^*^) is incubated to separate 
the ALP enzyme bound to IF. Para-nitrophenyl phosphate (pNPP) substrate is added 
and the following reaction is catalysed by ALP:
pNPP+HjO p-Nitrophenoxide+phosphate.
This can be detected by spectrophotometry at 405nm. and is inversely proportional to 
the amount of serum BI2 present, since only the activity o f ALP bound to IF is 
detected. The B12 concentration is calculated by the production of a standard curve.
The red cell folate assay uses the same principle with modification;
1) Pretreatment to release folate from red cell proteins
2) Folate binds to added Folate binding protein (Rl).
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3) Folate-conjugated ALP is added which competes with endogenous folate for RL
4) Enzyme activity detected by spectrophotometry is inversely proportional to 
endogenous folate concentration.
Quality assurance
The laboratory performing these assays is CPA accredited and performs satisfactorily 
in a national external quality assessment scheme (NEQAS). Internal quality control 
is monitored by the inclusion of three samples (Biorad, Hemel Hempstead, UK) of 
known B12 and red cell folate concentrations (high, normal and low). Results from a 
given assay batch are only accepted when the values for these controls are within the 
range provided by the manufacturers. Selected patient samples are repeatedly 
assayed to calculate intra-assay CVs (<5% in the laboratory).
5.3,3 Statistical analysis.
Calculations were performed using SPSS for Windows version 8.0 statistical 
software. Mean differences in normally distributed data between cases and controls 
were analysed by Student’s /-test, and by the paired /-test for differences between 
acute and convalescent samples. Unpaired skewed continuous variables, including 
tHcy concentrations, were analysed by the Mann Whitney U test, and paired data by 
the Wilcoxon Ranked Sign test. A two-tailed p value of <0.05 was considered 
significant. Results obtained from non-parametric analyses were checked by 
parametric testing of log transformed data. Continuous variables influencing tHcy 
concentration were assessed by stepwise multiple regression analysis that included
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age, red cell folate, serum B12 and serum creatinine concentrations in the model. 
Data were logarithmically transformed to a normal distribution if skewed, and 
multiple correlation coefficients (R) and partial Pearson correlation coefficients (r )^ 
calculated. The Beta weight, which expresses the change in the dependent variable in 
standard deviations that would result from a one SD change in the independent 
variable was calculated in order to predict the likely impact of any observed change 
in RCF, B12, or creatinine concentrations on tHcy concentrations. The distributions 
of clinical risk factors for arterial disease in cases and controls were compared by chi- 
squared analyses. Odds ratios and 95% confidence intervals were calculated using 
standard formulae.
5.4 Results
The outcome of patient recruitment and demography is described in chapter two. 
Data regarding homocysteine concentrations in the acute and convalescent periods 
are summarised in table 5.1. There was no statistically significant difference in the 
fasting median plasma homocystine concentrations in the acute phase compared to 
controls in females (p-0.58, Mann Whitney U test). In males there was a tendency to 
a higher median concentration in patients, but this was also not significant (p=0.09, 
Mann Whitney U test). In the 82 patients who underwent repeat testing the median 
fasting tHcy concentration increased significantly from 8.5|Limol/l {range 4,8-19.2} to 
lO.lpmol/1 {4.3-31.5} in the convalescent phase (p<0.001, Wilcoxon Ranked Signs 
test). This is illustrated in figure 5.3. O f these individuals, 56 had an increase, 25 a 
decrease, and one no change in tHcy between the acute and convalescent phases of 
their illness. In contrast to the acute phase, the tHcy concentrations in convalescent
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patients were significantly greater than in matched controls (n=82). In both female 
and male patients median concentrations were raised significantly (p=0.048 and 
0.035 respectively, Mann Whitney U-test).
Factors known to influence tHcy concentrations in subjects and controls were 
investigated by stepwise multiple regression analysis. The major determinants of 
logio tHcy were creatinine concentration (partial r^=0.35, p<0.001, Beta=0.42), red 
cell folate (partial r^=-0.32, p<0.001, Beta=-0.27) and B12 (partial f=-0.28, p<0.001, 
Beta=-0.22). In 25 patients the alteration in concentrations of red cell folate and B12 
between the acute and convalescent phases were assessed. The median red cell folate 
concentration in the acute phase (mean {SD} “ 223.2nmol/l {180.4}) did not differ 
significantly from that in the convalescent period (245.1 nmol/1 {172.3} p=0.061, 
paired /-test). Similarly there was no evidence of a significant reduction in B12 
concentrations in the convalescent period to account for the rise in tHcy (acute mean 
406pmol/l {243} versus convalescent mean 376pmol/l {128}, p=0.4, paired /-test. 
Alterations in renal function between the acute and convalescent periods were studied 
in a subgroup of 59 patients (37 men/22 women). There was a significant rise in 
mean serum creatinine when measured at least three months after acute stroke (acute 
mean{SD} 87.7pmol/l {19.5}, convalescent 94.1 pmol/1 {17.7}, p=0.006, paired 
samples /-test). It is calculated from the observed Beta weight o f 0.42 that this 
predicts a rise in mean tHcy concentration of 0.3 pmol/1.
Other factors known to influence tHcy were examined. No patient began smoking, 
and there was a non-significant increase in the number of patients prescribed
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medication associated with increased tHcy concentrations between acute CVA and 
follow-up (20/82 V 23/82 respectively, 0.28, p= 0.59).
5.5 Discussion
There are few reports of tHcy concentrations immediately following acute stroke, and 
these have recruited patients with a diversity of stroke aetiologies. This study was 
restricted to subjects with a single underlying pathophysiological process by 
recruitment of those with likely atherothrombotic stroke only. It was found that 
homocysteine concentrations were not significantly increased shortly after stroke, but 
that they rose significantly in the ensuing three months. There were no changes in 
factors commonly associated with mild hyperhomocysteinaemia to explain these 
findings.
Although red cell folate and serum B12 were significant inverse covariates, the rise in 
the convalescent phase tHcy was not associated with a corresponding reduction in 
their concentrations. Given that red cell folate and serum B12 reflect body stores, a 
longer follow up period may be required to detect such a change. Furthermore, this 
was assessed in a subset of the study cohort and it is therefore possible that a 
significant effect was undetected due to an inadequate sample size. The influence of 
the C677T polymorphism of MTHFR on tHcy is well documented, particularly when 
folate is also low (Selhub et al, 1993; Ma et al, 1996). It is clear that this is not a 
contributing factor in this study, since it is a constant in both periods. The number of 
patients taking medication associated with hyperhomocysteinaemia, such as
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methotrexate, phenytoin, carbamazepine or oral contraceptives, or the number who 
smoked did not significantly increase following acute stroke.
The observed increases in serum creatinine concentrations following acute stroke 
may be responsible in part for the rise in homocysteine concentrations observed in the 
convalescent period, since serum creatinine was a significant covariate. However the 
predicted increase in tHcy concentrations arising from this (O.Spmol/l) is much 
smaller than the observed median increase o f 1.6pmol/l. It is calculated that a mean 
rise of 73jimol/l would be required if creatinine were the sole determinant of tHcy 
concentration. An explanation for the observed rise in creatinine concentration is not 
apparent, but might reflect prescription of nephrotoxic drugs following stroke, or 
progressive decline in glomerular filtration in subjects with a diffusely diseased 
vasculature. The latter explanation is favoured since only 3/82 (3.6%) additional 
subjects were commenced on drugs associated with renal impairment (e.g. diuretics, 
angiotensin converting enzyme inhibitors or nonsteroidal anti-inflammatory drugs) 
following stroke. The noted deterioration in renal function may in fact reflect greater 
compliance with medication or tighter control of blood pressure in the convalescent 
phase.
In accordance with these observations, a previous smaller study reported that tHCy 
was not elevated in the acute phase of cerebral infarction, but noted that the median 
tHcy concentration was higher in 17 subjects resampled a median of 583 days later 
(Lindgren et al, 1995). However the median convalescent tHcy was not significantly
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different from controls. Recruitment of a larger sample size in this study determined 
that this difference was statistically significant. This provides an explanation for data 
from case control studies which report an increased prevalence of 
hyperhomocysteinaemia in stroke survivors (Graham et al, 1997; Yoo et al, 1998). A 
study of 12 subjects reported a similar rise in convalescent phase tHcy following 
acute MI (Egerton et al, 1996).
A possible explanation for these findings is that tHcy is elevated in the period 
predating stroke or MI, and that concentrations temporarily fall in the acute phase by 
an as yet undetermined mechanism. It has been suggested that this may be related to 
the acute phase response, with dilution of tHcy by increased synthesis of plasma 
proteins (Egerton et al, 1996). Furthermore, fasting tHcy concentrations are 
inversely related to oral protein intake (Stolzenberg-Solomon et al, 1999), and 
concentrations may therefore decline due to reduced dietary intake around the acute 
event. Data regarding alterations in oral protein intake immediately after stroke and 
the subsequent effect on tHcy are lacking, and were not formally assessed in this 
study. However a significant period o f reduced protein intake is considered unlikely 
in these patients, since they were admitted to an acute stroke unit where early 
nutritional supplementation was introduced if feeding difficulty was encountered. 
Furthermore the reduction in tHcy was not related to time of sampling in relation to 
stroke onset, which might be expected if  the fall in concentration was related to this 
mechanism (those sampled at 24 hours, geometric mean {range} 9.3 pmol/1 {3.6-23.2};
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at 36 hours 10.6 {5.0-32.3}; at 48 hours 8.8 {4.9-18.2}; 72 hours 8.4 {4.4-17.4}; at 
96 hours 9.3 {6.9-18.2}, p=0.41, ANOVA).
The suggestion that tHcy may not be a causative risk factor for stroke at all, and that 
plasma levels merely rise secondarily to stroke development, possibly in response to 
tissue injury (Dudman, 1999) is more favourable. This hypothesis, unlike the former, 
provides an adequate explanation for the fact that prospective studies have found a 
much weaker association (Perry et al, 1995; Giles et al, 1998; Alfthan et al, 1994; 
Verhoef et al, 1994) than retrospective studies conducted in survivors of stroke 
(Graham et al, 1997; Yoo et al, 1998). Further evidence for this view comes from the 
presently unexplained observation that although homozygosity for the T allele of the 
C677T polymorphism of MTHFR is associated with mild hyperhomocysteinaemia 
(Jacques et al, 1996; Markus et al, 1997), studies have failed to demonstrate this 
genotype as a risk factor for MI and stroke (Deloughery et al, 1996; van Bockxmeer 
et al, 1997; Markus et al, 1997; Brattstrom et al, 1998; Reuner et al, 1998; Harmon et 
al, 1999). To explain this apparent contradiction it has been suggested the TT 
genotype may only enhance risk when folate is low, or when other risk factors are 
present (Markus et al, 1997; Gardemann et al, 1999b), but further studies are 
required. In addition, obligate heterozygotes for Cysathionine B Synthase deficiency 
(i.e. parents o f children with homocystinuria) do not exhibit evidence o f carotid or 
femoral atherosclerosis despite elevated tHcy (de Valk et al, 1996). This lack of 
association between genetic abnormalities resulting in mild hyperhomocysteinaemia
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and arterial disease further weakens the hypothesis that such elevations in tHcy 
directly promote atherosclerosis and thrombosis.
It should be acknowledged that homocysteine has been linked in numerous in vitro 
studies with a diversity o f mechanisms that could potentiate atherothrombosis, 
including disrupted endothelial function, impaired protein C activation, increased 
thrombin generation and platelet aggregation (Harpel et al, 1996). However many of 
these studies were performed using supraphysiological concentrations of pure free 
single amino acid L-homocysteine and the data cannot be extrapolated to 
hyperhomocysteinaemia, where in addition to much lower concentrations, only 1% of 
tHcy is present as this reactive species. More recently transient moderate increases in 
tHCy following a methionine load have been associated with reversible disturbances 
in endothelium dependent arterial vasodilatation (Chambers et al 1999; Nappo et al,
1999), but data demonstrating that this promotes atherogenesis or thrombosis in 
humans in the longer term are lacking.
There is currently much interest in homocysteine as a risk factor for stroke, since it is 
possible to reduce plasma homocysteine concentrations in both healthy subjects (den 
Heijer et al, 1998) and patients with vascular disease (Malinow et al, 1998), with 
dietary folate, B12 and B6 supplementation. Several studies of homocysteine 
lowering agents in the secondary prevention of vascular disease are now underway 
(Hankey & Eikelboom, 1999). Many would argue that if  these studies show a 
reduction in vascular events accompanied by a reduction in tHcy then a causative
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association will be proved. However it should be noted that nutritional supplements 
may have a beneficial effect independently of an effect on homocyteine 
concentrations. For example folic acid enhances the synthesis o f nitric oxide on 
endothelial cells (Verhaar et al, 1998), and may therefore be beneficial by promoting 
platelet inhibition and vasodilatation. In such circumstances correction of 
hyperhomocysteinaemia would merely be an epiphenomenon.
The temporal relationship described in this study between tHcy and stroke requires 
further characterisation. In particular data regarding the tHcy concentration predating 
stroke, the subsequent change immediately afterwards, and the time taken for 
concentrations to rise subsequently are lacking. In order to determine the benefit of 
folic acid and B vitamin supplementation in secondary stroke prevention, the timing 
of these events should be considered when designing such trials.
In conclusion, plasma homocysteine concentrations were not statistically significantly 
elevated immediately after atherothrombotic stroke, but then increased in the 
convalescent period. The mechanism for these obsei*vations was not identified, and it 
is possible that tHcy increases as a result of the disease process itself. Proposals for 
further study to test this hypothesis are discussed in chapter seven.
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Group median tHcy
{jumol/1}
(range)
P
value
Female acute (n=47) 
control (n=47)
8.1 (4.8-32.3) 
7.6 (3.3-14.4)
0.58
convalescent (n=32) 
control (n=32)
10.0 (4.9-23) 
7.6 (3.3-14.4)
0.048
Male acute (n=59) 
control (n=59)
9.2 (4.4-22.8) 
8.7 (4.9-20)
0.09
convalescent (n=50) 
control (n=50)
10.2(4.3-31.5) 
8.2 (4.9-20)
0.035
Table 5.1. Median fasting total plasma homocysteine concentrations in the acute 
and convalescent phases of atherothrombotic stroke. Differences were assessed 
by the Mann Whitney U test.
Chapter Six
The contribution of Factor VII (FVII) gene 
polymorphisms to longevity in nonagenarians
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6.1 Background
In the previous chapters polymorphisms that might increase the risk of stroke have been 
discussed. This chapter considers polymorphisms that have been suggested to protect against 
stroke and MI, and which might therefore influence lifespan. The determinants of longevity 
in an individual are complex, and include environmental and behavioural factors (Christensen 
& Vaupel, 1996). However, family studies have indicated that genetic factors are important 
(Herskind et aZ, 1996), for instance an association with specific HLA loci has been described 
(Ivanova et al, 1998). Stroke and MI are the major causes of mortality in the western world, 
with particularly high rates in Scotland (Chambless et al, 1997). Longevity is therefore likely 
to be partly dependent on avoiding or delaying the onset of these conditions, and so 
polymorphisms affecting their risk might exert an influence. Indeed, differences in the 
distributions o f polymorphisms o f the apolipoprotein E, angiotensin converting enzyme and 
plasminogen activator inhibitor type 1 (PAI -I) genes have been described in centenarians 
compared to younger individuals (Schachter et al, 1994; Mannucci et al, 1997).
The Northwick Park Heart Study identified elevated factor VII activity (VIIc) as an 
independent risk factor for fatal MI in middle aged males (Ruddock & Meade, 1994), 
although others reported that an association between VIIc and coronary or cerebrovascular 
disease was lacking in older individuals (Folsom et al, 1993; Tracy et al, 1999). While the 
determinants of FVII concentrations are complex, including obesity and triglyceride level 
(Mermen et al, 1997), a genetic influence has been established. At the time of this study, 
three polymorphisms of the factor VII gene had been described which are associated with 
different factor VII levels: (1) a missense mutation of exon 8 with substitution of arginine by 
glutamine at position 353, designated R353Q; (2) a decanucleotide insertion sequence in the 
promoter region at position -323, designated 5’F7 ; and (3) a variable number o f tandem
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repeats in the hypervariable region 4 of intron 7 designated IVS7. Possession of the Q allele 
of R353Q, the A2 insertion allele of 5’F7, and homozygosity for the H7 allele of IVS7 are 
associated with lower FVIIc (Green et al, 1991; Bemardi et al, 1997). A more recent study 
claimed that homozygosity (and to a lesser extent heterozygosity) for the Q allele of the 
R353Q polymorphism, and homozygosity for the H7 allele o f the IVS7 polymorphism are 
protective against MI, possibly as a result of lower FVII concentrations (lacoviello et al, 
1998b). However, other studies have failed to confirm these observations ( Lane et al, 1996; 
Heywood et al, 1997; Doggen et al, 1998). To assess their contribution to longevity in a 
population with high mortality rates due to MI and CVA, the R353Q and IVS7 
polymorphisms were investigated, and evidence of enrichment of the genotypes previously 
associated with reduced MI risk was sought in a group of long-lived individuals living in the 
Grampian region of Scotland.
6.2 Methods
6.2.1. Subjects
113 consecutive subjects over the age of 90 who had a full blood count performed in the 
routine haematology laboratory at Aberdeen Royal Infirmary were identified by computer 
search between June and September 1998. The samples were retrieved after analysis and 
DNA extracted as described in chapter four. Samples from a sex matched control group were 
obtained from local blood donors under the age o f 45 who were free of symptomatic vascular 
disease. The protocol was approved by the Grampian Regional Ethical Committee.
6.2.2 R353Q analysis.
Principle
Substitution of Adenine for Guanine at position 10976 in exon 8 of the FVII gene results in 
the loss an msp 1 restriction endonuclease site, and in the substitution of arginine by glycine
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at position 353 of the translated protein. Amplification of the following primers (Green et al, 
1991) results in a 312 bp product:
sense 5’-GGGAGACTCCCCAAATATCAC-3’ 
antisense 5’-ACGCAGCCTTGGCTTTCTCTC-3 ’
The alleles can be discriminated electrophoretically, since digestion o f the R allele results in 
205, 67 and 40 bp fragments, whilst the Q allele results in 272 and 40 bp fragments.
PCR reaction conditions
Optimal conditions were determined by Mg titration. 4pl of 50ng/pl of genomic DNA were 
added to a thin walled PCR tube in a 25pl reaction. Each tube contained:
200ng genomic DNA. 
lOpmol each primer.
200pmol of dNTPs.
2 units of Taq DNA polymerase.
MgCb, varying between 0.5-5mM.
20mM trisHCl.
25mM KCl.
dHzO to a final volume of 25 pi.
The following conditions were applied using a Techne Progene thermal cycler (Cambridge 
UK): 1 cycle of dénaturation at 93 ° C for 180s, annealing at 55°C for 60s and extension at 
72°C for 120s; then 35 cycles of dénaturation at 93 ° C for 60s, annealing at 55 ° C for 60s and 
extension at 72 ° C for 120s). 15 pi o f product and 2 pi of loading dye were pipetted onto a 
2% agarose gel, electrophoresed at 75V for two hours, and stained with ethidium bromide.
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The brightest band was obtained using a Mg concentration of ImM, and this was included in 
all subsequent reactions. 4pl of DNA were added to a mastermix consisting o f the following 
(per tube):
• 2.5pi 1 OX Reaction Buffer.
• 0.5pl of dNTPs.
• 1 pi sense primer ( 1 Opmol/pi).
• 1 pi antisense primer ( 1 Opmol/pl).
• 1 pi 25mM MgCb.
• 0.2pl Taq polymerase.
• 14.8pl dHzO.
Restriction e n ^ m e  digest
• Conditions were optimised using subjects of known genotype. Initially 1 unit o f msp 1 
was used per reaction, but this resulted in incomplete digestion o f the QQ control sample, 
with a band at 205bp being obtained. The difficulty in discriminating between RQ and QQ 
genotypes was overcome on increasing the enzyme concentration tenfold. Thus the PCR 
product was incubated overnight at 37 °C with 10 units of msp 1. 15pi of product were 
added to a mastermix consisting of (per reaction):
• 3 pi Buffer Y.
• 1 pi msp 7(1 Ounits/pi).
• l l p l d H A
13 pi of the digest product and 2pl of loading dye were electrophoresed on 2% agarose gel for
1 hour to discriminate the alleles.
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Quality assurance
Each experiment included a blank (no DNA) to exclude reagent DNA contamination. 
Samples of known genotype were included in every experiment. Analyses were repeated at 
random to confirm the reproducibility of the method; two samples (one RR and one RQ) were 
genotyped three times each and the same result was obtained every time.
6.2.2 IVS7polymorphism analysis.
These analyses were kindly performed by Mr Neil Youngson, undergraduate student in the 
Department of Genetics at the University o f Aberdeen. lOOng genomic DNA were amplified 
using the primers (Marchetti et al, 1991): 
sense 5’-AATGTGACTTCCACACCTCC-3’ 
antisense 5 ’ -GATGTCTGTCTGTCTGTGGA-3 ’
A 25 pi reaction was performed eonsisting of:
• lOOng genomic DNA.
• ypmoles each primer.
• 200pM dNTPs.
• 2mM of MgClj were determined optimum.
• 50mMKCl.
• lOmMTris-HCl.
Initially the published cycling conditions (Marchetti et al, 1991), but no product was 
obtained. The cycling conditions described in chapter three for the HP A la /lb /lb  genotyping 
by enzyme digest were therefore applied and successfully yielded a product. Three alleles 
were identified by electrophoresis on 2% agarose according to the number o f monomeric
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repeat sequences obtained; H5 (5 monomers, 406bp), H6 (6 monomers, 443bp) and H7 (7 
monomers, 480bp). These are illustrated in figure 6.1. A blank and positive control DNA for 
the common IVS7 genotypes (H6H6, H6H7 and H7H7) were included in all experiments.
6.2.3 Statistical analysis.
Calculations were performed using the SPSS for Windows version 8.0 statistical software. 
The sex distributions, allele frequencies and distributions of the genotypes in the two groups 
were compared by chi squared analysis or Fisher’s exact test. A p value <0.05 was 
considered significant. Since QQ homozygotes were very rare, RQ and QQ genotypes were 
considered together.
6.3 Results
Samples were obtained from 113 subjects (86 female/ 27 male) over 90 years o f age (median 
age 96 years; range 90-103) and 100 (80 female/ 20 male) younger controls (median age 32 
years, range 19-44). There was no significant difference in the sex distribution between the 
groups (p=0.49). Samples which failed to yield a PCR product were repurified and the 
reaction repeated. R353Q genotypes were successfully elucidated in 108 subjects and 94 
controls, IVS7 genotype in 110 subjects and 100 controls, and both genotypes in 105 subjects 
and 94 controls.
The results are summarised in tables 6.1 and 6,2. Using Fisher’s exact test, linkage 
disequilibrium was seen between the two loci (p<0.002), with the rarer H7 and Q alleles 
occurring together more frequently than expected.
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The Q allele was enriched by 15.6% ( 0.111 v 0.096, p=0.61) and the H7 allele by 9.7% 
(0.395 V 0.360, p=0.45) in the nonagenarians compared to the control group, but these over­
representations did not reach statistical significance {table 6.1). The distribution of the 
specific genotypes previously associated with a reduced risk o f MI are shown in table 6.2. 
There is a non-significant tendency for both the RQ (0.222 v 0.17, p=0.36) and the H7H7 
genotypes (0.182 v 0.13, p=0.3) to be 49% and 40% more frequent in the long-lived 
respectively.
6.4 Discussion
The frequencies of the R353Q and IVS7 polymorphisms of the FVII gene in this study are 
similar to those previously described in a Northern European population, with the Q and H7 
alleles less common than in Southern Europe (Bemardi et al, 1997; Heywood et al, 1997). It 
has previously been reported that the FVII alleles associated with lower FVII concentrations, 
QQ, RQ and H7, are associated with a lower risk of MI (lacoviello et al, 1998b). As 
atherosclerotic disease is the leading cause of death in Scotland, accounting for almost half of 
all deaths in the cohort under consideration (Scottish Health Statistics, 2000), 
overrepresentation o f these alleles in nonagenarians was looked for. It was observed that the 
RQ and H7 alleles were overrepresented, but the difference did not reach statistical 
significance. There are two possible explanations for these findings. Firstly, there is no 
difference in frequencies between nonagenarians and younger subjects. If so, either the 
associations with MI previously reported are erroneous, or the effects of the polymorphisms 
are complex, perhaps only affecting events in the young or influencing non-fatal events. This 
viewpoint is supported by the observations that the role of VIIc in MI and CVA is itself 
subject to controversy. There does not appear to be a relationship between Factor VII and
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atherosclerosis per se, since no association with the extent of coronary (Broadhnrst et al, 
1990) nor carotid disease (Wu et al, 1992; Folsom et al, 1993; Sosef et al, 1994) is apparent. 
However, given that an association with acute thrombotic events has been observed 
(Broadhurst et al, 1990), especially those that were fatal (Ruddock & Meade, 1994; Heinrich 
et al, 1994), it was reasoned that FVII concentrations might influence longevity. The second 
possibility is that there is an effect, but one too small for this study to identify at a statistically 
significant level. The number of subjects recruited was determined in order to achieve 80% 
statistical power to detect a twofold greater number of QQ homozygotes in the extremely 
elderly, based on the genotype frequencies previously described (lacoviello et al, 1998b). 
This calculation was clearly an overestimate given the lower QQ geneotype frequency in 
Northern European populations. If the allele frequencies observed in this study reflect the 
true magnitude of any effect, it is calculated that between 750 (for the H7 allele) and 1600 ( 
for the Q allele) subjects are required for these differences to reach significance with 80% 
power. Following the completion of this study a study of Danish centenarians (Bladbjerg et 
al, 1999) reported that there was no association with FVII gene polymorphisms and 
longevity, but the sample size was again modest (n=187). Thus larger study populations are 
required to confirm any relation between FVII polymorphisms and longevity. An apparent 
difference might also be demonstrated with a relatively modest sample size if young patients 
with premature vascular disease were recruited as controls, to amplify the differences in 
cardiovascular risk between groups.
These data are more suggestive of an association between the Q allele and longevity than the 
findings of Mannucci et al, who found no difference in R353Q allele frequencies between 
Italian Centenarians and younger controls (Mannucci et al, 1997). The current study 
investigated the influence of the polymorphism in a very different population. Since
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cardiovascular mortality rates are three times those of Italy (Chambless et al, 1997), it was 
reasoned that any effect on longevity would be more apparent in this population. Indeed, the 
magnitude of effect of the Q allele, with 15.6% overrepresentation in nonagenerians, is 
comparable with the 25% underrepresentation observed in MI subjects (lacoviello et al,
1998), as MI is not the sole cause of death in the cohort under consideration. The IVS7 
polymorphism had not been investigated in the extremely elderly previously, although these 
data demonstrate linkage disequilibrium between the two loci.
Reaching the extremes of age may involve modification of genetically determined risk by 
environmental and other genetic factors. Indeed the Factor V Leiden polymorphism, which is 
associated with an increased risk venous thrombosis, is not associated with premature death 
and is not underrepresented in the extremely elderly (Mari et al, 1996; Rees et al, 1997). The 
current data suggest that polymorphisms of the FVII gene might exert a positive influence on 
longevity, but any such influence, if  present, is weak. This is in accordance with the view 
that the predominant influence on cardiovascular mortality in a Western population is 
environmental, and that any genetic predisposition inherited by an individual reflect the 
interactions of many loci, each with a weak influence. Thus, any effect o f FVII genotype on 
an individual’s cardiovascular risk would be modified by other factors, both environmental 
and genetic (Mermen et al, 1997; Ridker & Stampfer, 1999a). This viewpoint is supported by 
reports which have been published since the completion of this study, as the effect of the 
R353Q polymorphism on risk of MI is modified by smoking (lacoviello et al 1999). A 
further study from Italy demonstrated the alleles associated with lower FVII antigen 
concentrations were overrepresented in controls compared to young survivors of MI, 
suggesting a protective effect (Peyvandi et al, 2000). However a recent Dutch study did not 
identify an association (Lievers et al, 2000). Thus there appears to be an association between
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FVII gene polymorphisms and cardiovascular disease in the Italian population (lacoviello et 
al, 1998; Peyvandi et al, 2000) which is lacking in Northern European populations (Lane et 
al, 1996; Heywood et al, 1997; Doggen et al, 1998; Lievers et al, 2000; Feng et al, 2000), 
These differences might be related to the fact that these populations have lower allele 
frequencies than Italy, but it could also be speculated that different environmental factors 
modify the influence of genotype on FVII concentrations. Thus in the current study habitual 
differences in dietary fat intake between Scottish and Italian people might counteract any 
beneficial effect of the R353Q and IVS7 polymorphisms on the avoidance of stroke and MI.
In conclusion FVII gene polymorphisms claimed to be protective against MI were slightly 
overrepresented in nonagenarians, but a positive influence on longevity was not demonstrated 
since these differences were not statistically significant. A larger study is therefore required 
to investigate the effect of these polymorphisms on lifespan.
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480bp
443bp
406bp
H6H7 H6H6H5H6 H5H7 H7H7
ladder
Figure 6.1. IVS7 gene polymorphisms. Additional 
bands seen at different sizes correspond to the 
formation of heteroduplexes.
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Allele Cases no. (%) Controls no. (%)
R 192/216 (88.9) 170/188 (90.4)
0 24/216 (11.1) 18/188 (9.6)
H5 3/220 (1.4) 4/200 (2)
H6 130/220 (59.1) 124/200 (62)
H7 87/220 (39.5) 72/200 (36)
Table 6.1. R535Q and IVS7 polymorphism allele frequencies.
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Genotype Cases no (% ) Controls No (% )
RR 84/108 (77.8) 78/94 (83)
RQ 24/108 (22.2) 14/94 (14.9)
0 0 0/108 (0) 2/94 (2.1)
H7H7 20/110 (18.2) 13/100 (13)
H6H7 45/110 (40.9) 42/100 (42)
H6H6 42/110 (38.2) 41/100 (41)
H5H6 1/110 (0.9) 0/100 (0)
H5H7 2/110 (1.8) 4/100 (4)
H5H5 0 0
Table 6.2 Factor VII genotype frequencies.
Chapter seven
Conclusions
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This thesis examined proposed risk factors for thrombotic stroke, and sought 
evidence o f a causal relationship by examining both epidemiological and functional 
associations. Since it is impossible to accurately predict when an individual will have 
a stroke, and since the study of platelet function is labour intensive, prospective 
functional studies necessitate the study of a large number of subjects and 
considerable resource. While not truly prospective, it was considered that a study of 
platelet function and homocysteine concentrations both immediately after stroke and 
in the convalescent period would be informative.
In chapter four evidence of persisting platelet activation in patients with 
atherothrombotic stroke was demonstrated. Given that a substantial proportion of 
patients had significant pre-existing arterial disease (28% had a history of ischaemic 
heart disease, and 26% of previous stroke or TIA), and the observation that small 
absolute numbers o f activated platelets were detected, it could be suggested that these 
results reflect ongoing plaque inflammation and thrombosis observed in diffuse 
arterial disease. However this suggestion is not supported by the lack of correlation 
between platelet activation markers and plasma fibrinogen concentration, an indicator 
of the acute phase reaction. In addition, analysis of the 83 patients with no history of 
a previous clinical arterial event reveals persisting platelet activation in these subjects 
{table 7,1). This therefore suggests these individuals these patients have a 
constitutional predisposition to atherothrombotic stroke. It was established that this 
tendency was not related to polymorphisms of GPIIIa or GPIb, but it is possible that 
other polymorphisms might mediate this effect. It is planned to investigate an
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association between the C807T and G873A polymorphisms of the collagen receptor 
and platelet function in the cohort described in this thesis.
Platelet activation markers were not assessed in terms of clinical outcome in the 
study. A three-year mortality rate of 10% was recorded, but the cohort is too small 
and no statistical differences in platelet activation were observed between those who 
died and those who did not (data not shown). A retrospective assessment of the effect 
of platelet activation on disability score is therefore planned in order to establish 
whether a more subtle effect is present.
7.1 Polymorphism studies
Since this study was designed and completed there have been numerous studies of 
platelet glycoprotein polymorphisms and risk of vascular disease. These are 
discussed below, and the studies presented in this thesis are discussed in the context 
of these other reports.
7.1.1 Risk o f  ML
Weiss et al were the first to observe an association with MI and the lb  allele in 1996, 
in a small study of 71 survivors of MI compared with healthy age and sex matched 
controls. This was followed by several conflicting reports (table 7.2). There are no 
obvious methodological differences between these studies, but in general those that 
refuted an association (Ridker et al, 1997; Samani et al, 1997; Gardemann et al, 
1998; Mammotte et al, 1998; Bottiger et al, 2000) were larger than those in accord
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with Weiss et al (Zotz et al, 1998; Ardissino et al, 1999; Mikkelson et al, 1999). It 
could be suggested that a genetic influence on a multifactorial disease like MI might 
be apparent only in younger subjects, and that an effect was obscured in these reports 
by the inclusion of older patients who had accrued additional lifestyle risk factors 
(Garcia-Ribes et al, 1998). However, restricting analysis to young cohorts does not 
support this hypothesis (Scaglione et al, 1998; Bottiger et al, 2000). It has been 
suggested (Di Castelnuovo et al, 2001) that the lb  allele is not a risk factor for 
coronary heart disease per se, but is associated with MI at a younger age and 
thrombosis in situations of heightened risk, such as following ruptured coronary 
plaque (Zotz et al, 1998), angioplasty (Abbate et al, 1998) or coronary stenting 
(Kastrati et al, 1999; Walter et al, 1997). However, negative associations in this 
context have also been reported (Laule et al, 1999).
GPIb polymorphisms have been studied since they might affect platelet function by 
an effect on vWF binding in the high shear stress conditions observed in stenosed 
arteries. Few studies o f MI have been performed, and all have assessed small 
numbers of patients (table 7.3). Two did not observe an HP A 2a/2b genotype 
dependent influence overall in Japanese populations (Murata et al, 1997; Ito et al, 
1999), but the risk increased threefold on subgroup analysis of subjects under 60 
years who possessed the HPA 2b allele (Murata et al, 1997). These data require 
confirmation in larger studies, and in other ethnic groups.
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The C807T polymorphism of GPIa has been investigated {table 7.3) as the density of 
platelet surface collagen binding sites is influenced by genotype, which might affect 
platelet adhesion following plaque rupture (Kunicki et al, 1997), and similar 
inconsistencies are identified (Moshfegh et al, 1999; Croft et al, 1999; Corral et al,
1999). A very large study of 1057 patients with MI calculated a more modest 
influence on risk of MI than the smaller studies which identified a positive outcome 
(Santoso eZ a/, 1999).
7.7.2 Risk o f stroke.
The studies of stroke are summarised in table 7.4 and 7.5, and comparisons made 
with the current study. The present study is similar in terms of the number and mean 
age of subjects studied. Most failed to identify an influence o f HPA la /lb  genotype 
on stroke risk. It could be suggested that this occurred because a diversity of 
pathogenic mechanisms underlies stroke development, making it unlikely that a 
single gene could influence aetiology. The study in this thesis, unlike others, 
attempted to restrict analysis to atherothrombotic stroke. Despite this no HPA la /lb  
genotype dependent effect was observed. It may be that risk is only apparent in 
certain subgroups of the population, or in younger patients. Wagner et al (1998) did 
not observe an influence in 45 young women with stroke, but reported a statistically 
significant effect in the 10 women o f Caucasian origin in whom a cause of stroke was 
identified. Carter et al (1998) also identified an effect in 37 patients under 50 years, 
and in 218 non-smokers. These effects were observed in a very small number of 
patients, and was not confirmed by analysis o f the 79 subjects under 60 in this thesis.
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These associations may therefore be spurious, and require confirmation in larger 
studies.
Apart from the study described in this thesis, there are four other reports of the 
influence of GPIb polymorphisms on stroke risk. They are comparable in terms of 
the number and ages o f the patients recruited, and results are conflicting {table?.4). 
There has been a single case report of the C807T polymorphism o f GPIa and stroke 
risk (Carlsson et al, 1999), but the association in requires confirmation in larger 
studies.
7.1.3 Conclusions
A recent meta-analysis of HPA la /lb  (Di Castenuovo et al, 2001) combined the 
information from 34 studies, incorporating 9095 patients with IHD and 12508 
controls. The risk o f MI per se was modest, but statistically significant (OR 
1.10(1.03-1.18}). This increased in patients under 60 years (1,21 {1.05-1.38}) and in 
those undergoing revascularisation procedures (1.31 {1.1-1.56}), but is still small 
compared to the positive studies listed in table7.2. The influence of HPA la /lb  status 
is therefore unlikely to be o f clinical relevance in individual patients, but remains of 
interest when considering risk factors for vascular disease on a population-wide basis. 
Most studies to date have therefore been inadequately statistically powered to detect 
such subtle genetic effects. It was recently calculated that recruitment of at least 
4356 subjects would be necessary to demonstrate that HPA lb  is a risk for MI in a 
single population based study (Di Castelnuovo et al, 2001).
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A similar conclusion is reached from consideration of the data discussed in chapter 
six, FVII gene polymorphisms have been suggested to be protective against the 
development of MI, and the hypothesis that they are associated with an increased 
lifespan was tested. The ‘protective’ genotypes were slightly overrepresented in 
nonagenarians in comparison to younger subjects, but it was calculated that a much 
larger sample size would be required to demonstrate a statistically significant effect. 
A study of a larger cohort is therefore necessary. In addition, the study described in 
chapter six did not measure FVIIc to establish the influence of genotype on plasma 
levels. Although such a relationship has been described in other populations (Green 
et al, 1991; Bemardi et al, 1997; Peyvandi et al, 2000) measurement of VIIc in this 
study would be informative, given the possibility that genetic determination of VIIc 
levels is modified by the diet of the Scottish population.
Given these findings, and the lack of association between genotypes and stroke, it is 
concluded that any relationships (if present) are likely to be small, and may be 
modified by environmental and/or other genetic factors. These effects may therefore 
only be apparent in small subpopulations of the study cohort. This study avoided 
such subgroup analyses, since the sample size has insufficient statistical power to 
make such comparisons. Indeed it is possible that spurious associations may be 
encountered by chance alone if numerous analyses are performed. Association 
studies should therefore restrict analysis to comparisons for which the sample size is 
adequate (Ridker and Stampfer, 1998a). Such an approach would avoid unnecessary
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studies, exemplified by those of the angiotensin converting enzyme (ACE) I/D 
polymorphism and MI. Despite no evidence o f a functional effect, numerous 
modestly sized case control studies generated conflicting data, and the controversy 
was only resolved when a large (n=5000) study reported no association o f the D allele 
with MI (Keavney et al, 2000).
Although the study presented in this thesis is comparable in size to the others listed in 
table 7.4, it is clear with the benefit of hindsight that none o f these are large enough 
to convincingly demonstrate an allele dependent risk. Although the power 
calculation to determine sample size was based on HPA lb  frequencies, this study 
was primarily designed to determine whether an effect o f platelet genotype on 
function could be detected. From the outset the study was clearly underpowered to 
assess HPA la /lb  as an epidemiological risk factor, but the sample size is compares 
favourably with studies which have reported a functional consequence o f the 
polymorphism (table 7.5).
An association of HPA lb  with stroke observed in non-smokers only (Carter et 
al, 1998) is in contradistinction to reports o f Factor V Leiden (Rosendaal et al, 1997; 
Doggen et al, 1998) and the prothrombin G20210A mutation (Rosendaal et al, 1995; 
Doggen et al, 1999), which only observed an effect in smokers. The latter view is 
favourable since smoking produces a prothrombotic tendency, and it is plausible that 
this interacts with genes which also encourage thrombosis. Thus when considering
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candidate genes or possible gene-environment interactions, there should be evidence 
of a plausible biological mechanism as well as epidemiological association.
7.2 Functional studies of platelet polymorphisms
Studies assessing the functional consequences of the HPA la /lb  polymorphism are 
summarised in table 7.5, and comparisons with the studies in this thesis are drawn.
As with the epidemiological studies the data are conflicting, and some (Feng et al, 
1999; Michelson et al, 2000) reported greater responsiveness to agonists and 
increased activation in HPA lb-containing platelets compared with la  homozygotes, 
A ‘gene-dose effect’ was apparent as homozygous lb  platelets were more reactive 
than la /lb  heterozygous platelets. Others found no allele dependent differences 
(Corral et al, 1997) or identified increased reactivity in la  platelets (Lasne et al,
1997: Cooke et al, 1998). In chapter three no differences in basal fibrinogen 
activation or responsiveness to ADP were demonstrated in platelets from healthy 
donors. The present study was unable to assess homozygous lb  platelets since few 
subjects possessing this genotype were identified, but it was considered justifiable to 
search for functional effects in HPA la /lb  heterozygotes since this genotype accounts 
for the majority of subjects claimed at increased risk in epidemiological studies.
Studies which reported an effect of genotype on platelet function have been 
performed using in platelets from normal subjects, and it is unclear whether any of 
these small physiological differences are sufficient to contribute to disease
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pathogenesis. Goodall et al (1999) reported in 70 patients with stable coronary artery 
disease that lb  platelets from exhibited greater fibrinogen binding than la  platelets 
following stimulation with a weak agonist. 22 patients had a history of previous MI, 
but were sampled at a timepoint distant from the acute thrombotic event, and it 
remains uncertain whether these differences could result in acute thrombosis. The 
authors have subsequently increased the number of subjects studied and an allele 
dependent difference is no longer apparent, suggesting that statistical error accounts 
for their initial observations (Goodall et al, 2001, personal communication). Thus the 
study described in chapter four was designed to determine whether allele dependent 
differences in platelet function were apparent around the time of an acute thrombotic 
event. This is currently the only study in the literature to consider this, and no allele 
determined influence was observed. Although it is possible that there are small 
physiological differences between la  and lb  platelets, these were not observed at the 
time of stroke, and it is speculated that the cascade of events triggered by plaque 
rupture and tissue factor exposure swamp these relatively subtle effects.
7.3 Homocysteine as a causative risk factor.
It is apparent that demonstration of a plausible function effect of a genetic 
polymorphisms does not necessarily imply a causal relationship with stroke. This 
was discussed in chapter one, when in the case of fibrinogen B-gene polymorphisms, 
no increased risk o f vascular disease has been demonstrated despite an influence on 
plasma fibrinogen concentrations. As discussed in chapter four homozygosity for the 
T allele o f MTHFR C677T polymorphism is associated with increased plasma tHcy
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concentrations, but the genotype is not itself an independent risk factor for 
thrombosis (Brattstrom et al, 1998), and evidence of a plausible effect of tHcy on 
vascular risk is necessary. The relationship between plasma tHcy and acute 
thrombosis was therefore investigated in the stroke cohort. Median fasting tHcy 
concentrations did not statistically significantly differ between patients immediately 
after stroke and controls, but increased in the convalescent period so that 
homocysteine appears a significant risk factor when measured in the follow up 
period. These changes were not associated with alterations in factors known to 
influence tHcy, and the mechanisms of these changes require further study. There are 
two possible explanations for these observations:
• Homocysteine is not a risk factor fo r  stroke at all, but rises secondarily to the 
disease process.
• Homocysteine is a risk factor, and concentrations fa ll temporarily following 
stroke.
The former is favoured since it provides an adequate explanation for the fact that 
prospective studies have found a much weaker association than retrospective studies. 
However the mechanism of homocysteine increase requires identification. It has 
been suggested the rise in tHcy is a secondary phenomenon mediated by an increase 
in méthylation reactions in response to tissue damage, which generate S- 
adenosylhomocysteine, which is converted to Hey (Dudman, 1999). If  this is the case 
the magnitude o f increase might be correlated with the extent o f damage, and the
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relationship between changes in homocysteine concentration and infarct size 
(assessed by CT scanning) is therefore planned. A similar study relating plasma 
concentrations with infarct size in MI is also being considered. Although disability 
does not necessarily correlate with infarct size, an assessment of functional outcome 
might also be informative.
A mechanism to support the hypothesis that tHcy merely falls transiently at the time 
of a stroke has not been elucidated, and the relationship between the change in tHcy 
and acute phase markers requires further study, as it has been suggested 
concentrations fall by dilution from increased plasma protein synthesis (Egerton et al, 
1996). Furthennore a nutritional assessment would test the proposal that a reduction 
in dietary methionine intake following stroke might explain the observed changes.
7.4 Conclusions
In this thesis two main points are concluded. Firstly, the aetiology of 
atherothrombotic stroke is complex, and the influence of individual genetic risk 
factors may be small. Studies of genetic polymorphisms must be of appropriate 
statistical power to identify these subtle effects, and to investigate possible 
interactions. Furthermore plausible functional effects of polymorphisms should be 
sought to corroborate epidemiological associations. This could be studied in smaller 
cohorts, since one might reasonably expect to readily demonstrate an effect if it is 
clinically significant. Secondly, when considering the role o f a proposed pathogenic
139
risk factor such as homocysteine, it is important to investigate the temporal nature of 
the association with the clinical event. Caution must be applied when considering the 
results of retrospective studies, since they do not necessarily apply causality and are 
likely to overestimate risk compared with prospective studies.
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Appendix I. Reagents
i) Extraction o f  DNA from  leucocytes
• Nucleon BACC 2 DNA extraction kit (Nucleon Biosciences, Coatbridge, UK). 
Contains:
♦ Reagent A (red cell lysis solution) 420ml; lOmM Tris-HCL, 
320mM Sucrose, 5mM MgCb.bH^O, 1% Triton X-100.
♦ b) Reagent B 110ml.
♦ c) Sodium Perchlorate 26ml.
♦ d) Nucleon Resin 16ml.
• 100% Chloroform (BDH Laboratory Supplies, Poole, UK).
• 100% Ethanol (BDH Laboratory Supplies, Poole, UK). Diluted to 70% by 
adding 70ml to 30ml H 2O.
• IM Tris. 121.1 g Tris (2-Amino-2-(hydroxymethyl)-1,3-propanediol, 
Boehringer, Mannheim, Germany) added to IL H^O, adjusted to pH 8.0 and 
stored at 4 ° C.
• lOmM Tris/EDTA (TE). 10 ml of IM Tris added to 20ml o f 0.5M EDTA 
(18.612g ethylene diaminetetrahydroacetic acid, BDH Laboratory Supplies, 
Poole, UK in 100ml dHzO). Adjusted to pH8.0 and stored at 4°C .
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îi) H P A la / lb  and 2 a/2b genotyping by SSP-PCR.
• Thermus aquaticus (Taq) DNA polymerase 5 units /pi: (Appligene Oncor, a 
division o f Perkin Elmer, Foster City, California, USA).
• dNTPs: 2.5mM each of dATP, dTTP, dGTP and dCTP (Applied Biosystems, 
Warrington, UK).
• NW3 PCR reaction Buffer consisted of: 160mM(NH4)2SO4; 1.5mM MgCl2; 670 
mM Tris-HCl pH 8.8/0.1% w/v Tween 20 (purchased from University of 
Bristol, Department o f Transplantation, Bristol, UK).
• Primer mix: contained Ip l each of allele specific primer (3.5-5.0mM) and 
control primer (0.4-2.0mM). Kindly supplied by G. Cavanagh, National Blood 
Service, Newcastle.
• Cresol Red dissolved in dHjO, 10 mg/ml (Sigma Chemical Co., St Louis, 
USA).
• 1.5% Agarose gel: 1.5g Agarose (Appligene Oncor, Foster City, California, 
USA) dissolved in 100 ml of TBE.
• TBE. A lOx stock solution was made as follows: 108g Tris ((Amresco, Solon, 
Ohio, USA), 55g Boric acid (Amresco, Solon, Ohio, USA) and 40 ml of 0.5M 
EDTA (BDH Laboratory Supplies, Poole, UK), pH 8.0 were dissolved in
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200ml of dHzO and made up to a final volume of 1000ml. Working dilution 
prepared by the addition of 500ml to 4500ml dHjO.
Gene ruler lOObp DNA Ladder (MBI Fermentas, Vilnius, Lithuania).
Hi) HP A l a / l b  genotyping by PCR and restriction enzyme digest, and 
Factor VIIR353Q and IVS7 genotyping.
• Oligonucleotides, diluted to lOpmol/pl. Synthesised by Oswel Ltd, 
Southampton, UK.
• dNTP’s. 2x500pl containing 12.5mM each of dATP, dCTP, dGTP and dTTP 
(Bioline, London, UK).
• lOx Reaction Buffer. Contains 1ml o f lOOmM Tris-HCl (pH 8.8 at 25 °C), 
500mM KCl and 0.8% Nonidet P40 (MBI Fermentas, Vilnius, Lithuania).
•  MgClg. Contains 1ml o f 25mM MgCl; (MBI Fermentas, Vilnius, Lithuania).
• Thermus aquaticus (Taq) DNA polymerase. 5 units/pl (MBI Fermentas, 
Vilnius, Lithuania).
e MSP 1 (HPAII) restriction endonuclease, 10 units/pl (MBI Fermentas, Vilnius, 
Lithuania).
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Buffer YVTango restriction enzyme buffer (MBI Fermentas, Vilnius, 
Lithuania). Contains 1ml of 33mM Tris-acetate, lOmM magnesium acetate, 
66mM potassium acetate and 0.1 mg/ml bovine serum albumin (pH7.9 at 
37 °C).
Agarose and TBE as described above.
6x Loading dye solution (MBI Fermentas, Vilnius, Lithuania). Contains 
bromophenol blue and xylene cyanol, diluted 1:6 in dHjO prior to use.
Gene ruler™ 100 base pair DNA Ladder (MBI Fermentas, Vilnius, Lithuania).
iv) P latelet activation markers by whole blood flo w  cytometry.
• NajCitrate 3.2%. 3.2g (Trisodium citrate, BDH Laboratory supplies, Poole, 
UK) were dissolved in 100ml dHzO. One ml aliquots stored at 4°C .
• HEPES-Mg buffer. The following are dissolved in HjO to a final volume of 
100ml and adjusted to pH 7.4:
-NaCl 0.847g (Sodium chloride, BDH Laboratory Supplies).
-KCl 0.037g (Potassium chloride, BDH Laboratory Supplies). 
-MgS0 4 .7 H2 0  0.025g (Magnesium sulphate, BDH Laboratory Supplies). 
-HEPES 0.260g (N-2-hydroxyethyl piperazine-N-2-ethane sulphonic 
acid, monosodium salt, BDH Laboratory Supplies).
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•  The solution was filtered and stored in eppendorfs containing 450pl at 4 ° C.
• Phosphate buffered saline (PBS). The following were dissolved in dHgO to 
final volume of 100ml and adjusted to pH 7.4:
-NaH2P0 4 .2 HzO 0.035g (Sodium dihydrogen orthophosphate, Fisher 
Scientific Ltd, Loughborough, UK).
-NagHPO^anhydrous 0.107g (diSodium hydrogen orthophosphate
anhydrous, BDH Laboratory Supplies, Poole, UK).
-NaCl 0.850g (Sodium Chloride, BDH Laboratory Supplies, Poole, UK).
• The solution was filtered and stored at 4°C. The solution was replaced 
weekly.
• ADP. (Adenosine diphosphate, Sigma, St. Louis, USA). ImM solution was 
diluted 1:10 by adding 5pl to 45 pi of PBS.
• PMA (phorbol 12-myristate 13-acetate, Sigma, St Louis, USA). Dissolved 
1 mg/ml in DMSO(dimethyl sulfoxide, Sigma, St Louis, US A).One ml aliquots 
stored at -20 °C prior to use. This was diluted 1:100 by adding 5 pi to 495 pi 
PBS.
• FITC (fluorescein isothyocyanate) conjugated murine anti-Keyhole limper 
hemocyanin (KLH) IgG, isotype control (Becton Dickinson, California, USA). 
50pg / ml. IgG. 1:25 dilution to yield 2ng/pl final concentration.
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• PE (phycoerythrin) conjugated mouse anti-KLH IgG, isotype control (Becton 
Dickinson , California, USA). 50pg/ml IgG. 1:25 dilution to yield 2ng/pl final 
concentration.
• FITC conjugated monoclonal mouse antiCD61 (GPIIIa) antibody (Dako, 
Glostrup, Denmark). lOOpg/ml. 1:50 dilution to yield 2ng/pl final 
concentration.
• PE conjugated monoclonal mouse anti-CD62P (P-Selectin) antibody 
(Immonotech, Marseilles, France). 40pg/ml. 1:20 dilution to yield 2ng/pl 
final concentration.
• FITC conjugated polyclonal rabbit antifibrinogen antibody (Dako, Glostrup, 
Denmark). lOOpg/ml. 1:50 dilution to yield 2ng/pl final concentration.
• Flowcheck^^ fluorospheres (Coulter, Luton, UK). Fluorescent microspheres 
for assessment of optical alignment of fluidics. HPCV(half peak coefficient of 
variation) of <3% is considered acceptable for assay o f cell surface markers.
• Immunobrite beads. EPICS Immuno-brite Standards Kit (Coulter, Luton, UK). 
Five vials of fluorospheres o f known intensity:
I) Blank
11 ) Medium-low
I I I )  Medium-reference
IV) Medium-high
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V ) Brite
Run each day to determine voltage settings required to attain identical 
fluorescence. In practice this did not require adjustment.
v) Total plasm a Homocyst(e)ine by reverse phase H PLC and
fluorescent detection.
• QC plasma. Pooled normal plasma obtained from healthy volunteers and 
stored at -20 ° C in 200pl aliquots for single use.
• L-Homocystine standard (Sigma, St Louis, USA). 67.6mg dissolved in 100ml 
dHjO to a concentration of 50pM. 20pl in lOOpl yields a final concentration of 
lOpM.
• 10% TBP. Tri-n-butylphosphine 0.81g/ml (Sigma, St Louis, USA) 0.1ml 
added to 0.9ml dimethylformamide 0.94g/ml (Sigma, St Louis, USA).
• 10% TCA. lOg trichloroacetic acid (BDH Laboratory Supplies, Poole, UK) 
dissolved in 100ml dHjO.
• SBD-F (ammonium-7-fluoro-3,l,3-benzoxadiazole sulphonate, Fluka, New- 
Ulm, Switzerland). 0.5mg added to 1ml of borate buffer, thoroughly mixed 
and stored in the dark, as light sensitive. Prepared daily.
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• O.IM Borate buffer. One litre made by dissolving 38.14g disodium 
tetrahydroborate (BDH Laboratory Supplies, Poole, UK) and 0.74g ethylene 
diaminetetra-acetic acid (BDH Laboratory Supplies, Poole, UK) in 1000ml of 
dH^O.
• 3M NaOH. 6g sodium hydroxide (BDH Laboratory Supplies, Poole, UK) in 
50ml dHjO.
• Orthophosphoric acid 85% solution, ‘HiPerSolv for HPLC™ (BDH Laboratory 
Supplies, Poole, UK).
• Mobile phase: 7% ACN, acetonitrile (Rathburn Chemicals Ltd, Walkerbum, 
Scotland, UK)70g in 1000ml 25mM Potassium dihydrogen phosphate buffer 
(BDH Laboratory Supplies, Poole UK). To make up 2L of mobile phase: 6.8g 
buffer in 1840ml dHjO, plus 140ml ACN. Adjusted to pH 2.2 by the addition 
of 20ml neat orthophosphoric acid.
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A pp en d ix  I I
PATIENT INFORMATION SHEET
Homocysteine is a chemical in the blood (an amino 
acid) which, when raised, is associated with narrowing 
of the arteries (atherosclerosis). This can cause such 
illnesses as 'heart attacks' (myocardial infarctions) 
and 'strokes' (cerebrovascular accidents).
Platelets are the cells in the blood which help it to 
clot when an injury occurs. It is thought that 
abnormal platelets may be involved in inappropriate 
clotting, resulting in heart attacks or strokes.
The purpose of this study is to investigate the role of 
these two mechanisms in the causation of strokes.
This will involve taking a sample of your blood to 
measure homocysteine levels and to look at whether the 
platelets are working normally. We will also
investigate why homocysteine is raised. This may be 
due to your diet or to an inherited predisposition. A 
sample of your DNA will be extracted from the blood to 
look at this.
The samples will all be taken together after you have 
fasted from midnight the night before. They will be 
taken at 9am so that you do not have to wait long for 
breakfast.
In order for the results to make sense we also need to 
do the same tests on a control who has not had a 
stroke. It would be very helpful if you could nominate 
a friend or relative of the same sex and roughly the 
same age who would be willing to have this done. It 
would involve them attending hospital in the morning 
after fasting from midnight to have some blood taken.
It will also be necessary to repeat the tests after 3 
months and you will be sent an appointment to attend 
the outpatient clinic for this.
All the tests are done in an anonymous fashion and are 
completely confidential. If you refuse to take part it 
will in no way influence your treatment in hospital.
Dr D Meiklejohn. June 1997
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VOLUNTEER CONTROL INFORMATION SHEET
Thank you for considering giving a blood sample as a control sample for the study 
investigating the causes of stroke.
We are investigating the role a chemical in the blood called homocysteine has in 
the cause of strokes, since it has been suggested that raised homocysteine levels 
can cause narrowing o f arteries (atherosclerosis). In addition we are interested in 
looking at platelets. These are the cells in the blood that help it to clot after an 
injury. It is thought that they may be overactive in patients with a stroke causing 
inappropriate blood clotting.
We are interested in assessing if these features have a role in patients in Aberdeen, 
and are taking blood from newly diagnosed stroke victims at A.R.I.. In order to 
assess the results properly it is necessary to test the blood o f someone who has not 
suffered a stroke.
If you agree to this a sample of approximately 30 ml of blood will be taken from 
you in the morning at the clinic, after you have fasted from midnight and before 
you have your breakfast. This will be as soon as possible after you arrive so that 
you don’t have to wait too long before eating. This will be used to extract DNA 
and to check vitamin and homocysteine levels.
The blood tests are done anonymously and the results are kept strictly 
confidential. You will also be asked to fill in a questionnaire about your eating 
habits.
Dr D Meiklejohn June 1997.
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CONSENT BY PATIENT/VOLUNTEER TO PARTICIPATE IN:
“STUDY OF PLATELET GENOTYPE, GENETIC DETERMINANTS OF 
HYPERHOMOCYSTEINAEMIA AND PLATELET AND COAGULATION 
ACTIVATION IN THROMBOTIC STROKE.”
Name of patient/volunteer:...........................
Principal Investigator: Dr D Meiklejohn
I have read the patient/volunteer information sheet and have had the opportunity
to discuss the details with...........................  and ask questions. The doctor has
explained to me the nature and purpose of the tests to be undertaken. I understand 
fully what is proposed to be done.
I have agreed to take part in the study as it has been outlined to me, but I 
understand that am free to withdraw from the study or any part of the study at any 
time I wish and that this will not affect my continuing medical treatment in any 
way.
I understand that these trials are part of a research project designed to promote 
medical knowledge, which has been approved by a Joint Ethical Committee, and 
may be of no benefit to me personally.
I agree to a sample o f my DNA being kept so that further investigations may be 
performed at a later time, as new 
developments in medical science arise.
I understand tat the tests are done on an anonymous basis, so that it will not be 
possible to disclose my individual results.
I also understand that where appropriate, my General Practitioner will be 
informed that I have taken part in the study.
I hereby fully and freely consent to participate in the study which has been fully 
explained to me.
Signature of patient/volunteer:.........................
date:.........................
I confirm that I have explained to the patient/volunteer named above, the nature 
and purpose o f the tests to be undertaken.
Signature o f investigator:........................
date:........................
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NOTE: FILE ONE COPY IN SECTION A OF PATIENT NOTES AND
RETAIN A SECOND COPY
IN IT IA L  ASSESSMENT CHECK L IS T
1) Name and unit no:..............
Affix addressograph here
2) Age/dob
3)CT confirmation of completed infarct rather than TIA 
or haemorrhage. Yes/No (delete as appropriate).
4)Excluded AF/ valvular heart disease. Yes/No.
5)Past Medical History (HBP, DM, Hyperlipidaemia)
6)Drug History (Aspirin/NSAIDs or B12/Folate/B6)
7)Dietary assessment ????
8) Family History of atherosclerosis. Yes/No
9) Details of friend/relative who will be control
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9) Sample checklist (tick):
i) 2x 4ml EDTA; FBC and ref to haematology
; frozen sample for homocysteine.
ii) Ix 10ml Na Cit; for platelet genotype and
coagulation markers.
Hi) Ix 4ml EDTA; for DNA extraction.
iv) 2x 5ml clotted ; 1 to haem for B12/folate.
; 1 stored for B6 estimation.
v) Ensure lipids checked on routine biochemistry 
vi) Coag screen if not routinely done.
Comments
9) Consent form signed Yes/No.
10) Date for repeat testing given Yes/No 
If yes, when.......................
D Meiklejohn. June 1997.
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DONOR PLATELET STUDY 
S tu d y  num ber............................
Donor Number..................
Date of sample.............
Previously Tested Genotype..............
Sample Taken for DNA extraction Yes/No 
Repeat Genotyping performed? Yes/No Date
Result of repeat genotyping.............
Consent form signed Yes/No
Results
GPIIIa GPIIIa GPIIIa FBG % FBG +
% +CD62P +CD62p ADP %
H2, +PMA H2,
FL2/FL1 FL2/FL1 
/  /
D Meiklejohn March 1998
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